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Abstract
This dissertation explores phase I dose-finding designs in can-
cer trials from three perspectives: the alternative Bayesian dose-
escalation rules, a design based on a time-to-dose-limiting toxicity
(DLT) model, and a design based on a discrete-time multi-state (DTMS)
model.
We list alternative Bayesian dose-escalation rules and perform a
simulation study for the intra-rule and inter-rule comparisons based
on two statistical models to identify the most appropriate rule under
certain scenarios. We provide evidence that all the Bayesian rules
outperform the traditional “3+3” design in the allocation of patients
and selection of the maximum tolerated dose.
The design based on a time-to-DLT model uses patients’ DLT
information over multiple treatment cycles in estimating the probabil-
ity of DLT at the end of treatment cycle 1. Dose-escalation decisions
are made whenever a cycle-1 DLT occurs, or two months after the
previous check point. Compared to the design based on a logistic re-
gression model, the new design shows more safety benefits for trials
in which more late-onset toxicities are expected. As a trade-off, the
new design requires more patients on average.
The design based on a discrete-time multi-state (DTMS) model
has three important attributes: (1) Toxicities are categorized over a
v
distribution of severity levels, (2) Early toxicity may inform dose es-
calation, and (3) No suspension is required between accrual cohorts.
The proposed model accounts for the difference in the importance of
the toxicity severity levels and for transitions between toxicity lev-
els. We compare the operating characteristics of the proposed design
with those from a similar design based on a fully-evaluated model
that directly models the maximum observed toxicity level within the
patients’ entire assessment window. We describe settings in which,
under comparable power, the proposed design shortens the trial. The
proposed design offers more benefit compared to the alternative design
as patient accrual becomes slower.
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1Introduction
1.1 Motif
Phase I oncology trials determine the highest dose that does not result in a
prohibitive toxicity, which is known as the maximum tolerated dose (MTD).
This determination is accomplished by designating the doses given to consecutive
patient cohorts based on the toxicity responses from patients in the trial who have
already received the treatment. As the initial opportunity to observe patients’
responses to a new drug or treatment combination, a phase I trial is a fundamental
component of the most important steps in drug development.
Current methods to determine the MTD in phase I cancer trials are inefficient
and may unnecessarily prolong the duration of the trial. We address multiple is-
sues in phase I clinical trials. These problems include that toxicity is typically
treated as a binary outcome and accrual is regularly suspended. We develop
methods that stem from an acknowledgment that toxicity is actually a set of het-
erogeneous adverse outcomes that can range from mild to severe. In addition, we
develop approaches that do not require suspension of accrual. Thus our approach
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wastes less information and can be completed more rapidly.
In this dissertation we explore phase I oncology trials from three perspectives:
In Chapter 2 we investigate a set of Bayesian dose-assignment rules applied to
two popular probability models, and recommend appropriate rules under certain
scenarios. In Chapter 3 we describe a phase I dose-finding design based on a time-
to-event model with flexible patient cohort depending on the occurrence of dose-
limiting toxicity (DLT) within the first cycle of treatment, the development of
which I participated in during an internship with Novartis Oncology. In Chapter
4 we propose an adaptive phase I dose-finding method based on a discrete-time
multi-state model that incorporates the toxicity level and allows patients’ partial
toxicity information to inform decision about dose-escalation.
Traditional up-and-down algorithms are the most commonly used methods
for phase I dose-finding trial designs. Among them is the well known “3+3”
design, for which decisions are made according to the performance of the current
cohort of three patients, in addition to the performance of the previous cohort
at the same dose. Model-based dose-assignment rules developed over the past
decades have also gained attention in cancer trials. A common dose-escalation
rule used in conjunction with the continual reassessment method (CRM), is based
on point estimates for the probability of toxicity at each dose. Using that rule, for
example, the next cohort is treated at the dose with a mean posterior probability
of toxicity closest to the prespecified target probability, e.g., 30%. Other model-
based methods include partitioning the posterior probability of toxicity into sub-
intervals: Dose-escalation is then based on the toxicity region of the current dose
(Bekele et al. , 2010) or on augmenting the likelihood of achieving a target
toxicity interval without causing prohibitive levels of toxicity (Neuenschwander
et al. , 2008). Conaway et al. (2004) proposed an asymmetric loss function
that penalizes the toxicity probability according to its relative relationship to the
2
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target. Each of the above dose-assignment rules has merit in certain scenarios.
To compare the performance among the various rules, we investigate each rule’s
operating characteristics by changing a set of key decision parameters (described
in detail in Chapter 2) and evaluate which method performs the best under each
decision parameter configuration.
Traditional phase I dose-finding designs usually determine the maximum tol-
erated dose (MTD) based on the frequency of DLTs observed within the first
cycle of treatment (e.g., 21 days). These designs ignore toxicity beyond the first
cycle. To incorporate late-onset toxicity into the dose-escalation decisions, we
propose a design based on a Bayesian time-to-DLT model. While dose-escalation
decisions are based on the estimates of the DLT rate at the end-of-cycle 1, the
model allows toxicity beyond cycle 1 to inform the end-of-cycle-1 DLT rate. The
next dose-escalation point is decided by the occurrence of the cycle 1 DLT. The
operating characteristics of the proposed design are compared with those from a
design based on a Bayesian logistic regression model that uses the frequency of
the cycle 1 DLT for the decisions of dose-escalation (see Chapter 3).
Standard phase I trials dichotomize toxicity based on whether the toxicity is
dose limiting. For example, if grade 4 fatigue is a dose-limiting toxicity, while
fatigue of grade 1, 2, and 3 are considered not dose limiting, then grade 1 fa-
tigue and grade 3 fatigue are treated identically. These approaches are designed
to address early toxicity of a sufficiently high level. However, due to the ethi-
cal requirement to limit the exposure of patients in the trial to toxic doses, the
above methods discard useful information and lead to other problems. First,
if a drug results in delayed toxicity and the trial’s accrual rate is high, many
patients may be treated at overly toxic doses before clinicians are aware of any
toxicities. Second, different categories of toxicity are not equal importance and
do not occur independently. If several categories of toxicity are likely to occur, a
3
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model describing the progression within category is needed. To better character-
ize toxicity severity levels and their transitions, we propose a phase I dose-finding
design based on a discrete-time multi-state model (see Chapter 3). The new de-
sign considers patients’ partial toxicity information when guiding dose-escalation
decisions and does not require accrual suspension between patient cohorts, which
shortens the trial duration. An alternative design by Bekele et al. (2009) based
on a fully-evaluated model is also introduced for comparison. The alternative
design directly models the maximum observed toxicity level within the patient
assessment window and therefore requires accrual suspension between patient
cohorts (see Chapter 4).
1.2 Background and significance
1.2.1 Phase I cancer trials
This section explains concepts that are fundamental to phase I cancer trials,
including trial conduct, trial features, ethical concerns, and the definition of tox-
icity, etc. Readers who are familiar with these concepts may want to skip this
section.
The components of a typical phase I design are the prespecified doses to be
evaluated, a starting dose, cohort sizes, methods for designating the appropriate
doses for consecutive cohorts, a maximum sample size, stopping rules, and a cri-
terion for choosing the maximum tolerated dose (MTD) at the trial’s conclusion.
A common definition of the maximum tolerated dose (MTD) is a dose associated
with a clinically permissible degree of toxicity, which if surpassed could result in
prohibitive degree of toxicity (Chevret, 2006). Trial conduct in phase I generally
involves three basic processes: designating the starting dose for the first group
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of patients; designating doses for successive patient cohorts based on the toxicity
data accumulated from patients in the trial who already received the treatment;
and monitoring the trial for early stopping if there is evidence of excessive drug
toxicity or enough evidence to identify the MTD.
According to Storer (1989), the challenges of designing and analyzing a phase
I trial include the use of a small sample of heterogeneous patients who are eval-
uated over a relatively long period. This approach is taken partially because of
the ethical requirement to use a conservative approach when escalating doses,
combined with a relatively subjective assessment of what does and does not con-
stitute toxicity, and the potential need to assess response in patients who drop
out of the study early for reasons other than toxicity.
The definition of toxicity, which varies substantially for different trials, may be
generally considered as detrimental secondary effects of treatment that render the
treatment unfeasible (Thall & Lee, 2003). However, in oncology trials, some level
of toxicity is expected. Unlike patients in phase I trials for nonlethal conditions
or diseases, patients with cancer often choose to enroll in a phase I trial because
their disease has progressed to a terminal stage and they have few or no other
treatment options. Such patients accept the risk of severe toxicity along with
the possibility that treatment may prolong their lives. Oncology clinicians also
accept the risk of severe toxicity, even presuming that better clinical results can
be achieved when patients receive higher doses of anti-tumor drugs. Thus, a
common goal is to treat patients at the highest tolerable dose.
1.2.2 Bayesian adaptive design
This section provides an essential introduction to Bayesian adaptive designs that
will help readers better understand subsequent sections. Readers who are familiar
5
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with the Bayesian paradigm and the basic concept of the adaptive design may
want to skip this section.
An adaptive design prospectively allows the investigators to modify the de-
sign parameters, while patients are still enrolling into the trial by periodically
examining the accumulating data. Modifications include early stopping, extend-
ing accrual, adding or dropping treatment arms, assigning patients to arms that
are performing better, etc.
In addition to the goal of learning as efficiently and as rapidly as possible,
the aim of adaptive designs is also to treat patients as effectively as possible. A
phase I cancer trial should be designed to limit the treatment of patients at both
ends of the spectrum: at low, non-therapeutic doses and at severely toxic doses.
A good adaptive design navigates between the two ends of the spectrum (Berry,
2004). Furthermore, a Bayesian adaptive design provides a straightforward and
flexible way to determine dose selection.
The Bayesian approach uses probability to characterize all uncertainty regard-
ing parameters, which distinguishes it from the frequentist approach. The term
“Bayesian” refers to mathematical work first proposed by Thomas Bayes (circa
1702 - 1761), who is best known for a theorem that takes his name. The essence
of Bayes’ theorem is that, given some data and some hypothesis, the posterior
probability that the hypothesis is true is proportional to the likelihood multiplied
by the prior probability. The likelihood characterizes the data, whereas the prior
specifies the belief in the hypothesis before the data were observed.
A Bayesian analysis explicitly states that:
• The prior distribution carries historical knowledge of the credibility of dif-
ferent values of a treatment effect,
6
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• The likelihood is the credibility of different values of the treatment effect
based on data from the trial, and
• The posterior distribution is a combination of the prior distribution and the
likelihood, constructing an assessment of the treatment effect.
The above process focuses on how information gleaned in a trial should influ-
ence researchers’ assessment of the treatment effect. Bayes’ rule enables the dis-
tribution of the parameter under investigation to be updated as new observations
accumulate. The Bayesian approach to clinical trials involves ongoing revisions
of the assessment of the treatment effect during the trial as more information
is gathered. This allows for greater flexibility in the trial and is a discriminat-
ing characteristic between Bayesian and frequentist approaches to clinical trials
(Berry, 2006).
Fundamental differences in Bayesian and frequentist methods in randomized
trials are listed in Table 1.1(Spiegelhalter et al. , 1999).
1.2.3 Traditional designs for phase I dose-finding
This section introduces the traditional phase I dose-finding design and provides
the basis for the development of a new design and model in later chapters.
Traditional methods in phase I dose finding include the “3+3” algorithm, the
continual reassessment method (CRM) by O’Quigley, et al. (1990) and escalation
with overdose control (EWOC) by Babb, et al. (1998).
1.2.3.1 “3+3” algorithm
The standard methodology in the classical “3+3” design is as follows:
• Treat 3 subjects at the starting dose level Di
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1.2 Background and significance
• If 0/3 subjects experience dose-limiting toxicity (DLT), escalate to dose
Di+1
• If 1/3 or more subjects experience DLT, treat 3 more subjects at dose level
Di
• If 1/6 subjects experience DLT, escalate to dose Di+1
• If 2/6 or more subjects experience DLT, MTD = Di−1
Dose escalation stops when one-third of the subjects experience DLT at a given
dose level. The MTD is then the next lower dose level.
Storer (1989) lists four single-stage designs and two two-stage designs based on
the “up and down” scheme, and compares them with several simple alternatives
with regard to the conservativeness of the design and with regard to the point
and interval estimates of the MTD.
This approach is easy; however, it is not adjustable. The method is “designed”
to estimate the MTD as a 33rd percentile, thus it is inappropriate if some other
toxicity probability is targeted. The requirement that 3 subjects be exposed
to the experimental treatment at each dose level leads to the inefficient use of
patients. In addition, the design is conservative, it usually underestimates the
MTD. Chapter 2 will describe a modified “3+3” method in comparison with other
Bayesian decision rules.
1.2.3.2 Continual reassessment method (CRM)
The continual reassessment method (CRM) (O’Quigley et al. , 1990) is a
Bayesian dose-finding algorithm that is based on a parametric model and a fixed
target toxicity rate. The method continually updates our knowledge about the
9
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therapy and treats patients at a level that is closest to the target level, as in-
dicated by the current accumulated data. The model under the CRM assumes
that toxicity probability is conditional on the dose and requires a set of fixed
probabilities that are associated with the dose levels. The one-parameter power
model for the CRM is
pθ(d) = c
θ
d, d = 1, · · · , D, θ > 0
where the values of cd are monotonically increasing, prespecified (skeleton) prob-
abilities.
The dose with the estimated mean probability of toxicity that is closest to
the target level is designated for each patient cohort. A fixed sample size n is
decided upon at the beginning of the study and the estimated MTD is the dose
that would be allocated to patient n+1 were they to be included in the trial. The
CRM represents one of the earliest uses of Bayesian methods in clinical trials
to determine the MTD of a drug. It is flexible in allowing variations in the
number of patients who are give each dose, and can integrate the dose-limiting
toxicity (DLT) rates that are expected for different therapies. Extensions of the
CRM include the time-to-event continual reassessment method (TITE-CRM) by
Cheung et al. (2000), which allows patients to enter a trial without suspending
accrual and thus decreasing trial duration. We will adopt the dose-assignment
rule from the CRM as one alternative Bayesian decision rule to compare with
other methods in Chapter 2.
1.2.3.3 Escalation with overdose control (EWOC)
Escalation with overdose control (EWOC) was first proposed by Babb et al.
(1998). This method allows the clinician to prespecify the dose levels that will
be available in a phase I trial such that the anticipated proportion of patients
10
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who experience toxicity is set at a specified value α, which is called the feasibility
bound. This is accomplished by computing the posterior cumulative distribu-
tion (CDF) of the MTD at the time of each dose assignment. For the kth dose
assignment, the posterior CDF of the MTD is given by
pk(γ) = Prob{MTD ≤ γ|Dk},
where Dk denotes the data at the time of treatment for the kth patient. pk(γ) is
the conditional probability that γ is an overdose given the data currently avail-
able. Based on this, EWOC selects for the kth patient the dose level dk such
that
pk(dk) = α.
EWOC is designed to consider all the data that has accumulated when desig-
nating a dose for a new patient cohort. This method also controls the probability
of toxicity. Neuenschwander et al. (2008) proposed a similar dose-assignment
rule by categorizing the toxicity interval into sub-intervals and selecting the dose
by maximizing the toxicity in the target interval while controlling the toxicity
within the excessive and unacceptable interval. We will describe this rule as an
alternative Bayesian decision rule in Chapter 2.
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2Bayesian Dose-Assignment Rules
for Phase I Dose Finding in
Cancer Trials
This chapter investigates four published Bayesian dose-assignment rules for phase
I dose finding in cancer trials. Each rule involves decisions based on the posterior
probability of toxicity. A modified “3+3” design is also introduced for compar-
ison as it remains widely used in phase I dose finding trials. There are no new
methodologies or dose-assignment rules developed in this chapter. Our purpose
is to use simulation to demonstrate the appropriateness of the rules under certain
scenarios. The metric we use to evaluate the performance of each rule is the per-
centage of trials in which the true maximum tolerated dose (MTD) is successfully
declared, and the average proportion of patients assigned to each dose. The five
dose-assignment rules are:
12
• CRMr - the rule in the CRM design by O’Quigley et al. (1990) that assigns
the next cohort to the dose with the posterior mean probability of toxicity
closest to the target;
• MaxTI - the rule by Neuenschwander et al. (2008) that assigns the next
cohort to the dose with the maximum posterior probability of toxicity within
a target interval;
• ODC - the overdose control rule by Bekele et al. (2010) that is based on
the probability that the current dose is overly toxic;
• Loss - the rule by Conaway et al. (2004) that defines the closeness of an
estimated probability of toxicity to the target based on a loss function; and
• the modified “3+3” algorithm.
In addition to their specific dose-assignment rules, all trials in our study are
conducted as follows: The first cohort of patients are treated at the lowest dose
and their clinical responses to treatment are fully observed. The probability
model (or toxicity information) provides the current estimates of toxicity proba-
bility at each of the available doses. The next cohort of patients is then treated at
the dose determined by the corresponding dose-assignment rule. Proceeding by
sequentially updating the probability of toxicity for the available doses, the trial
stops at a fixed sample size (if it is not stopped early) and provides an estimate
of the MTD.
We begin this chapter by introducing two probability models on which the
four Bayesian decision rules are based. Then we provide the five dose-assignment
rules and universal over-dose control criteria. We proceed with the simulation
studies and close this chapter with a discussion.
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2.1 Two probability models
2.1.1 Bayesian beta/binomial model
The Bayesian beta/binomial model assumes that the individual probability of
toxicity for each dose follows a binomial distribution. Let yi(d) be the toxicity
status for patient i on dose d, where Yi(d) = 0 indicates no toxicity within the
patient’s assessment window (e.g., treatment cycle 1), and Yi(d) = 1 indicates
toxicity within the patient’s assessment window. Define θd as the probability of
experiencing toxicity within the patient’s assessment window for dose d. Let n(d)
be the total number of patients on dose d. The general form of the contribution
to the likelihood attributed to each patient is given by the following equation:
L(yi(d)) = θ
I(yi(d)=1)
d [1− θd]I(yi(d)=0)
where θd is a priori distributed as
θd ∼ beta(αd, βd).
Define n1(d) as the number of patients experiencing toxicity within the as-
sessment window and n1(d) =
∑n(d)
i=1 I(Yi = 1). Since the binomial and beta
distributions are conjugate, the posterior distribution of θd | data is
θd | data ∼ beta(αd + n1(d), · · · , βd + (n(d)− n1(d))).
The above beta/binomial model provides the posterior distribution of the toxicity
probability for each dose based on the current data. There remains a problem
that the probability of toxicity may not be monotone across doses. In order to
keep the monotone relationship of toxicity across doses, we apply an isotonic
transformation (similar to that of Li et al. 2008) on the posterior probability of
14
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toxicity. The pooled adjacent violators algorithm (PAVA; Robertson et al. 1988)
is applied to borrow information across doses. To carry out the Bayesian isotonic
transformation, we first draw posterior sample vectors of θ | data and then apply
PAVA to θ | data. Denote θordd as the order-restricted probability of toxicity for
dose d after PAVA. The algorithm guarantees that θorddj ≥ θorddi for dj > di.
2.1.2 Logistic regression model
The two-parameter logistic regression model parameterizes the probability of tox-
icity using the logistic transformation,
Logit{θd} = α + βlog(d/d∗), β > 0 (2.1)
where (α, β) are model parameters, d∗ is a reference dose, and α is interpreted as
the odds of toxicity at d∗. The ability to combine data from patients treated at
different dose levels is a valuable feature of the regression model. This effectively
enables us to “borrow” statistical strength, which can result in more accurate
predictions of the future outcomes for patients who are given specific doses for
the drug. Compared to the one-parameter CRM model introduced in Chapter
1, the logistic model imparts greater flexibility and more accurately depicts the
dose-toxicity curve that characterizes the treatment under evaluation.
Assuming that the prior for (α, β) follows a bivariate normal distribution,
the prior mean and covariance matrix can be calibrated by pre-specifying several
percentiles (e.g., 2.5%, 50%, 97.5%) of toxicity probability for each dose based on
empirical evidence. More details of prior tuning are described by Neuenschwander
et al. (2008).
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2.2 Five dose-assignment rules
Let θ∗ = 0.33 be the target toxicity rate. The four Bayesian dose-assignment
rules summarize the relationship between θd | data and θ∗ in different ways. The
fifth “rule”, the modified “3+3” algorithm, which is not based on a probability
model.
2.2.1 CRMr by O’Quigley et al.
CRMr, which is based on the dose-escalation concept of the CRM design proposed
(O’Quigley et al. , 1990) assumes a monotonic dose-toxicity relationship. The
“target” toxicity level was first introduced in this method for a life-threatening
illness, when there is no immediate possibility of assessing the relative advantages
of the treatment against its toxicities. In addition to the notion of sequentially
updating the dose-toxicity relationship as new observations become available,
patients are always treated at the dose that has a current probability of toxicity
closest to the target. At the end of the trial, the estimated MTD is the dose that
would be assigned to the next patient cohort were it be introduced in the trial.
2.2.2 MaxTI by Neuenschwander et al.
Neuenschwander et al. (2008) incorporated uncertainty about θd into their ap-
proach to phase I trial design. They were motivated by potential problems at the
beginning of the trial because of the CRMr approach of using point estimates for
the probability of toxicity and ignoring the uncertainty about θd. Motivated by
this concern, Neuenschwander et al. (2008), let θ1, θ2 and θ3 be the cutoff values
of the toxicity probability, where 0 < θ1 < θ2 < θ3 < 1. MaxTI classifies the
probability of toxicity into four categories:
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Under-dosing: θd ∈ (0, θ1]
Targeted toxicity: θd ∈ (θ1, θ2]
Excessive toxicity: θd ∈ (θ2, θ3]
Unacceptable toxicity: θd ∈ (θ3, 1]
Summarizing θd by toxicity intervals, a dose is designated according to the
likelihood of achieving the targeted toxicity interval in addition to limiting the
likelihood of prohibitive toxicity.
The rationale of controlling the overly toxic doses under MaxTI is comparable
to that of EWOC (described in Chapter 1), where the overdose criteria is defined
by a feasibility bound α as the posterior probability of exceeding the MTD. MaxTI
is flexible in selecting appropriate toxicity intervals for the specific treatment.
The upper bound for the target toxicity interval θ2 is often set to be 0.33 to
allow a maximum of 1 toxicity to occur out of 3 dose administrations estimating
the MTD. The intervals for excessive and unacceptable toxicity are sometimes
combined for overdose control (e.g., ≤ 70%).
2.2.3 ODC by Bekele et al.
Unlike other Bayesian dose-assignment rules, in which decisions are made upon
evaluation of all available doses, decisions for ODC are made upon evaluation of
the current dose’s posterior probability of toxicity above the target (Bekele et
al. 2010). Define ξd = Pr(θd > θ
∗|data). The method partitions the unit interval
into three subintervals by the cutoff values 0 < ξ < ξ < 1 and defines that toxicity
at dose d is inconsequential if ξd < ξ, permissible if ξ ≤ ξd ≤ ξ, and prohibitive
if ξd > ξ. The selection of cutoff values reflects the investigator’s preference for
a more aggressive or more guarded treatment approach. Information obtained
from computer simulations should also be used to direct the selection of cutoff
17
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values so that desirable operating characteristics are achieved. Reasonable cutoff
values are 0.05 ≤ ξ ≤ 0.30 and 0.70 ≤ ξ ≤ 0.90 (Bekele et al. 2008).
Given the above definitions, we describe below the dose-assignment rule.
• Treat the first cohort of patients at the lowest dose and fully observe the
toxicity information of each cohort of patients.
• If the current dose evinces inconsequential toxicity, then escalate to the next
higher dose that does not evince prohibitive toxicity. Stay at the current
dose if the next higher dose evinces prohibitive toxicity.
• If the current dose evinces permissible toxicity, then stay at the current
dose.
• If the current dose i evinces prohibitive toxicity and i > 1, then de-escalate
to the highest dose less than i that is not prohibitively toxic. If i = 1 or
all doses evince prohibitive toxicity, then stop the trial early and declare
failure due to prohibitive toxicity of the drug.
• At the end of the trial, select a dose with either inconsequential or permis-
sible toxicity having a posterior mean of θd closest to the target θ
∗.
Other than being flexible in selecting appropriate cutoff values for overdose
control, ODC is straightforward in making decisions based on the current dose’s
toxicity information with the intrinsic mechanism of “borrowing strength” across
doses through the probability model. It relies more on the current dose rather
than treating all doses equally (e.g., tried and untried doses). This may avoid
assigning more patients to a higher untried dose that is later found to be too toxic.
We will perform a simulation study to explore the impact of different values of
ξd on the operating characteristics.
18
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2.2.4 Loss by Conaway et al.
Conaway et al. (2004) proposed a loss function for defining how close an es-
timated probability of toxicity is to the target. The loss associated with an
estimated θˆd and a target probability θ
∗ is given by the following equation,
Loss(θˆd , θ
∗) =
{
γ(θ∗ − θˆd), ifθ∗ > θˆd
(1− γ)(θˆd − θ∗), ifθ∗ ≤ θˆd. (2.2)
Let R(d) be the risk associated with the loss and R(d) = E(L(θˆd, θ
∗)|data).
The next cohort of patients is always treated at the dose with the lowest R(d).
At the end of the trial, the estimated MTD is the dose that has an estimated
mean probability of toxicity that is closest to the target.
The operating characteristics of loss is largely decided by the value of γ in
equation 2.2. A value of γ = 0.5 corresponds to a symmetric loss. An asymmetric
loss penalizes toxicity greater than the target level differently than that below
the target level. For each dose, the ratio of the penalty with {θ : θ < θ∗} and
{θ : θ > θ∗} is γ
1−γ . A smaller γ assigns less penalty to the probability of toxicity
below the target and thus makes it conservative in selecting the next dose. On
the other hand, a larger γ assigns less penalty to the probability of toxicity above
the target, which makes it easier to escalate doses. We will perform a simulation
study to explore the different choices of γ and will recommend an appropriate γ
that is a compromise between the two notions.
2.2.5 Modified “3+3” algorithm
The traditional “3+3” algorithm treats a maximum of 6 patients at any dose
level. To keep the trial sample size the same across the different methods, we
modify the algorithm to allow more than 6 patients to be treated at one dose:
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• Treat 3 subjects at the starting dose di.
• If ≤ 1/6 subjects experience toxicity on current dose di, escalate to dose
di+1.
• If between (1/6, 1/3) subjects experience DLT on di, treat 3 more subjects
at the same dose level di.
• If 1/3 subjects experience DLT on di, treat 3 more subjects at di if 3 subjects
have been treated on di, otherwise de-escalate to dose di−1.
• If > 1/3 subjects experience DLT on di, de-escalate to dose di−1 or stop the
trial early.
At the end of the trial, the estimated MTD is the highest dose that has a
toxicity rate below 0.33.
This “3+3” approach represents a guarded clinical approach and therefore
usually underestimates the MTD. Also, it estimates the MTD only at the 33rd
percentile, and does not allow for adjustments when the target MTD is not at
that level.
2.3 Universal overdose control criteria
In addition to each individual rule, we impose two universal overdose control cri-
teria for the Bayesian dose-assignment rules: (i) Skipping doses when escalating
is not allowed, even though the model may recommend so. (ii) For the rules
without built-in overdose control criteria, the selected dose’s probability of toxi-
city above the target must be no larger than a threshold (i.e., ξd ≤ 0.8). MaxTI
has its own built-in criteria on ξd and may not be in compliance with the second
criteria defined above (ii).
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2.4 Simulation study
2.4.1 Scenarios
The simulation study aims to learn how the above dose-assignment rules perform
under certain dose-toxicity scenarios. There are 5 dose levels in each scenario.
The sample size for each trial is fixed at 30. Trials may be stopped early for
futility using the overdose control criteria. Each cohort of 3 patients is fully ob-
served before assigning patients to the next cohort. We generate 6 representative
scenarios within the dose-toxicity domain, as shown in Figure 2.1. The probabil-
ity of toxicity is above the target for all doses in scenario MTD-0; therefore, the
overdose control criteria should stop the trial early in this scenario. For scenario
MTD-1, the lowest dose is the true MTD and the probability of toxicity for all
other doses is significantly above the target. For scenario MTD-2, dose 2 is the
true MTD and the probability of toxicity for dose 1 and dose 3 show significant
separation from that of dose 2. For scenario MTD-3, dose 3 is the true MTD and
the probability of toxicity for dose 2 and dose 4 are very close to that of dose
3. For scenario MTD-4, dose 4 is the true MTD and has very low probability of
toxicity; whereas dose 5 is very toxic. For scenario MTD-5, the highest dose is
the true MTD.
We first elicit priors for the two model parameters, and proceed with investi-
gating the individual rules. When the rule parameters influence the rules, such
as in MaxTI, ODC and Loss, we change the parameters and compare the per-
formances to capture the impact of different parameter values on the operating
characteristics. The five rules are then lined up for comparison. The simulations
are divided into two parts by the two probability models. The modified “3+3”
algorithm, which is not based on any probability model, is introduced first.
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Figure 2.1: Dose-toxicity scenarios. The dashed lines mark the target toxicity
rate of 0.33. The names of the scenarios reflect the true MTD.
22
2.4 Simulation study
2.4.2 Prior specification
For simulations based on the beta/binomial model, we derive the prior probability
of toxicity by specifying αd and βd for each dose. The prior mean probability of
toxicity for each dose is listed in Table 2.1. Each prior carries information for one
patient.
Table 2.1: Prior specification for θd ∼ beta(αd, βd) for the beta/binomial model
d1 d2 d3 d4 d5
αd 0.128 0.159 0.172 0.210 0.241
βd 0.871 0.841 0.827 0.790 0.759
E(θd) 0.128 0.159 0.172 0.210 0.241
For simulations based on the logistic regression model, we assume that the
priors for α and logβ are noninformative and follow a bivariate normal distribu-
tion, as defined in Table 2.2. The 95% confidence interval, mean and median for
the prior probability of toxicity are shown in Figure 2.2.
Table 2.2: Bivariate normal prior specification on (α, logβ) for the logistic regres-
sion model
E(α), E(log(β)) Standard deviation Correlation
(-3,-0.6) (3.16,0.76) 0.4
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Figure 2.2: The 95% confidence interval, mean and median of the prior probability
of toxicity for the Bayesian logistic regression model
2.4.3 Operating characteristics based on modified “3+3”
algorithm
Operating characteristics for the modified “3+3” algorithm are shown in Figure
2.3. The top bars represent the average proportion of patients assigned to each
dose. The bottom bars represent the MTD selection percentage for each dose.
The unshaded space of the top bars marks the average proportion of patients not
assigned to any dose (out of 30) due to early stopping. The unshaded space of
the bottom bars marks the percentage of trials in which no dose is declared as
the MTD due to early stopping.
For scenario MTD-1 where dose 1 is the true MTD, 71.5% of the trials stopped
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early and failed to declare the MTD. The average total number of patients per
trial for this scenario is 14.63. Overall, the algorithm performs very conservatively
in dose escalation and in MTD declaration for trials for which the target toxicity
rate is 0.33. Among the 6 scenarios, scenario MTD-4 yields the best performance.
2.4.4 Operating characteristics for CRMr
Figures 2.4 and 2.5 show the operating characteristics for the CRMr based on
the beta/binomial model and the logistic regression model, respectively, with the
particular priors specified in Section 2.4.2. Compared with the modified “3+3”
algorithm, the CRMr performs less conservatively. For scenario MTD-0, in which
all doses are too toxic, CRMr performs aggressively by assigning more patients to
doses with higher toxicity based on the beta/binomial model (Figure 2.4). This
occurs primarily because the point estimation of the posterior probability ignores
uncertainty and is problematic at the beginning of the trial. For scenario MTD-4,
in which the toxicity of the true MTD is very low, CRMr performs aggressively
based on the logistic regression model (Figure 2.5). The performances of CRMr
are appropriate for the other scenarios. A lower value for the overdose control
criteria (e.g., ξd ≤ 0.6) will make the performance less aggressive for scenarios
MTD-0 and MTD-4. However, this will make the performances too conservative
for the other scenarios.
2.4.5 Operating characteristics for MaxTI
In investigating MaxTI, we combine the excessive and unacceptable toxicity inter-
vals for overdose control. Therefore only θ1 and θ2 need to be specified. The cutoff
points for under-dosing and target toxicity intervals are (θ1 = 0.167, θ2 = 0.333).
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Figure 2.3: Operating characteristics based on the modified “3+3” algorithm.
The x-axis represents 6 scenarios. The top bars represent the average proportion
of patients on each dose. The bottom bars represent the MTD selection percentage
for each dose.
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Figure 2.4: Operating characteristics for CRMr based on beta/binomial model.
The x-axis represents 6 scenarios. The top bars represent the average proportion
of patients on each dose. The bottom bars represent the MTD selection percentage
for each dose.
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Figure 2.5: Operating characteristics for CRMr based on logistic regression
model. The x-axis represents 6 scenarios. The top bars represent the average
proportion of patients on each dose. The bottom bars represent the MTD selection
percentage for each dose.
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The values for θ1 and θ2 are selected in alignment with the modified “3+3” algo-
rithm for comparison purpose. The selected dose’s probability of toxicity beyond
the target interval is controlled such that ξ ≤ (0.5, 0.7, 0.9). Note that the built-
in overdose control criteria in MaxTI are not in compliance with the universal
overdose control criteria (ii) defined in Section 2.3. Figures 2.6 and 2.7 show the
operating characteristics based on the beta/binomial model and the logistic re-
gression model, respectively, with the particular priors specified in Section 2.4.2.
As shown in the figures, the higher upper-bound of ξ results in a more aggressive
performance. For scenario MTD-4, in which the true MTD (dose 4) is very safe
and the adjacent increased dose is very toxic, the beta/binomial model yields
the ideal performance by assigning most of the patients to the true MTD and
successfully declaring the MTD at the end of the trial. For scenario MTD-5, in
which the highest dose is the true MTD, the Bayesian logistic regression model
yields the ideal performance. MaxTI performs appropriately in patient allocation
and dose selection overall. The choice of toxicity intervals and overdose control
should be guided by the specific trial characteristics and simulation results.
2.4.6 Operating characteristics for ODC
Decisions based on ODC will escalate the dose if the probability of overdose for
the current dose is below ξ, and de-escalate if it is above ξ. We fix ξ at 0.2 and
choose ξ = (0.7, 0.8, 0.9). The operating characteristics are shown in Figure 2.8
for the beta/binomial model and in Figure 2.9 for the Bayesian logistic regression
model, with the particular priors specified in Section 2.4.2. Overall, a higher
value of ξ yields a more aggressive performance in patient allocation because
higher ξ makes the algorithm unlikely to reject higher doses. As a special case
based on the logistic regression model (Figure 2.9), in scenario MTD-4, in which
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the true MTD (dose 4) is very safe and the next higher dose is very toxic, the
next lower dose (dose 3) is more often selected as the MTD when ξ increases. The
individual trial simulation shows that dose 3 is more likely to be selected as the
MTD when more patients are assigned to dose 5. This is because having more
patients assigned to dose 5 allows the logistic regression model to borrow more
strength from dose 5. As a consequence, the probability of toxicity for each dose
is overestimated due to the high occurrence of toxicity on dose 5. Using overdose
control, the posterior mean toxicity of dose 3 is therefore more likely to be the
one closest to the target. ODC performs appropriately in patient allocation and
dose selection overall.
2.4.7 Operating characteristics for Loss
To investigate the impact of γ on the design performance, we select γ to be
(0.4, 0.5, 0.7). The operating characteristics are shown in Figure 2.10 for the
beta/binomial model and in Figure 2.11 for the logistic regression model, with the
particular priors specified in Section 2.4.2. Overall, the rule performs consistently
in that more information from patients information on higher doses results in a
lower percentage of likelihood that the higher doses are declared as the MTD. For
scenarios MTD-3, MTD-4 and MTD-5 based on the beta/binomial model (Figure
2.10), where γ = 0.4, no patients are assigned to dose 5 due to a higher penalty
on overdose in the loss function. For trials that declare dose 5 as the MTD in the
above scenarios, toxicity information on dose 5 is based entirely on the prior and
the toxicity information for other doses. Therefore, for γ < 0.5, the trial is at risk
of declaring a higher dose as the MTD due to a lack of information. The MTD
selection is significantly improved with a slightly higher proportion of patients
assigned to dose 5 when γ = 0.7. Overall, γ = 0.7 yields the best performance
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among the three choices of γ.
This section describes an intra-rule analysis based on two probability models
to give readers a perspective on each rule’s performance. Some decision rules
involve specification of the parameters that summarize the posterior distribution
of toxicity probability. The selection of decision parameters should be guided by
trial characteristics as well as simulation outcomes to fully investigate possible
scenarios. The next section describes an inter-rule comparison to better identify
the appropriate rules under certain scenarios.
2.4.8 Comparison between dose-assignment rules
For comparison purposes, we select within each decision rule the parameter that
yields the best overall operating characteristics, based on the particular priors
specified in Section 2.4.2. For Loss, γ = 0.7. For MaxTI, ξ = 0.7. All the
other Bayesian rules are restricted by the overdose control criteria with ξ ≤ 0.8.
The operating characteristics of the five rules for each scenario based on the
beta/binomial model are described in Section 2.4.8.1; those based on the Bayesian
logistic regression model are described in Section 2.4.8.2. In the figures that
accompany the descriptions, each pair of bars represents the average proportion
of patients assigned to each dose and the MTD selection percentage for each dose.
2.4.8.1 Comparison based on the beta/binomial model
This section summarizes the inter-rule performance based on the beta/binomial
model for the 6 scenarios illustrated in Figures 2.12 throughout 2.17. Compared
to the model-based Bayesian decision rules, the modified “3+3” algorithm per-
forms very conservatively in patient allocation and MTD selection. For scenarios
in which the lower dose is the true MTD (e.g., MTD-0 to MTD-2), MaxTI slightly
35
2.4 Simulation study
(a
)
S
ce
n
ar
io
M
T
D
-0
P
.to
x
=
(0
.50
,0.
55
,0.
60
,0.
65
,0.
70
)
P
ro
po
rt
io
n 
of
 P
a
tie
nt
s 
on
 D
os
es
Proportion
γ=
0.4
γ=
0.5
γ=
0.7
00.51
d5 d4 d3 d2 d1 d0
D
os
e 
Se
le
ct
io
n 
Pe
rc
e
n
ta
ge
Dose selection %
γ=
0.4
γ=
0.5
γ=
0.7
050100
(b
)
S
ce
n
a
ri
o
M
T
D
-1
P
.to
x
=
(0
.30
,0.
50
,0.
55
,0.
60
,0.
65
)
P
ro
po
rt
io
n 
of
 P
a
tie
nt
s 
on
 D
os
es
Proportion
γ=
0.4
γ=
0.5
γ=
0.7
00.51
d5 d4 d3 d2 d1 d0
D
os
e 
Se
le
ct
io
n 
Pe
rc
e
n
ta
ge
Dose selection %
γ=
0.4
γ=
0.5
γ=
0.7
050100
(c
)
S
ce
n
a
ri
o
M
T
D
-2
P
.to
x
=
(0
.10
,0.
30
,0.
50
,0.
60
,0.
70
)
P
ro
po
rt
io
n 
of
 P
a
tie
nt
s 
on
 D
os
es
Proportion
γ=
0.4
γ=
0.5
γ=
0.7
00.51
d5 d4 d3 d2 d1 d0
D
os
e 
Se
le
ct
io
n 
Pe
rc
e
n
ta
ge
Dose selection %
γ=
0.4
γ=
0.5
γ=
0.7
050100
(d
)
S
ce
n
ar
io
M
T
D
-3
P
.to
x
=
(0
.10
,0.
25
,0.
33
,0.
40
,0.
60
)
P
ro
po
rt
io
n 
of
 P
a
tie
nt
s 
on
 D
os
es
Proportion
γ=
0.4
γ=
0.5
γ=
0.7
00.51
d5 d4 d3 d2 d1 d0
D
os
e 
Se
le
ct
io
n 
Pe
rc
e
n
ta
ge
Dose selection %
γ=
0.4
γ=
0.5
γ=
0.7
050100
(e
)
S
ce
n
a
ri
o
M
T
D
-4
P
.to
x
=
(0
.05
,0.
05
,0.
10
,0.
15
,0.
60
)
P
ro
po
rt
io
n 
of
 P
a
tie
nt
s 
on
 D
os
es
Proportion
γ=
0.4
γ=
0.5
γ=
0.7
00.51
d5 d4 d3 d2 d1 d0
D
os
e 
Se
le
ct
io
n 
Pe
rc
e
n
ta
ge
Dose selection %
γ=
0.4
γ=
0.5
γ=
0.7
050100
(f
)
S
ce
n
a
ri
o
M
T
D
-5
P
.to
x
=
(0
.05
,0.
10
,0.
15
,0.
25
,0.
30
)
P
ro
po
rt
io
n 
of
 P
a
tie
nt
s 
on
 D
os
es
Proportion
γ=
0.4
γ=
0.5
γ=
0.7
00.51
d5 d4 d3 d2 d1 d0
D
os
e 
Se
le
ct
io
n 
Pe
rc
e
n
ta
ge
Dose selection %
γ=
0.4
γ=
0.5
γ=
0.7
050100
F
ig
u
re
2
.1
0
:
O
p
er
at
in
g
ch
a
ra
ct
er
is
ti
cs
fo
r
L
o
ss
w
it
h
d
iff
er
en
t
γ
b
as
ed
on
th
e
b
et
a/
b
in
om
ia
l
m
o
d
el
.
In
ea
ch
sc
en
ar
io
,
γ
=
(0
.4
,0
.5
,0
.7
)
fr
o
m
le
ft
to
ri
gh
t.
T
h
e
to
p
b
ar
s
re
p
re
se
n
t
th
e
av
er
ag
e
p
ro
p
or
ti
on
o
f
p
a
ti
en
ts
on
ea
ch
d
os
e.
T
h
e
b
o
tt
om
b
ar
s
re
p
re
se
n
t
th
e
M
T
D
se
le
ct
io
n
p
er
ce
n
ta
ge
on
ea
ch
d
os
e.
36
2.4 Simulation study
(a
)
S
ce
n
ar
io
M
T
D
-0
P
.to
x
=
(0
.50
,0.
55
,0.
60
,0.
65
,0.
70
)
P
ro
po
rt
io
n 
of
 P
a
tie
nt
s 
on
 D
os
es
Proportion
γ=
0.4
γ=
0.5
γ=
0.7
00.51
d5 d4 d3 d2 d1 d0
D
os
e 
Se
le
ct
io
n 
Pe
rc
e
n
ta
ge
Dose selection %
γ=
0.4
γ=
0.5
γ=
0.7
050100
(b
)
S
ce
n
a
ri
o
M
T
D
-1
P
.to
x
=
(0
.30
,0.
50
,0.
55
,0.
60
,0.
65
)
P
ro
po
rt
io
n 
of
 P
a
tie
nt
s 
on
 D
os
es
Proportion
γ=
0.4
γ=
0.5
γ=
0.7
00.51
d5 d4 d3 d2 d1 d0
D
os
e 
Se
le
ct
io
n 
Pe
rc
e
n
ta
ge
Dose selection %
γ=
0.4
γ=
0.5
γ=
0.7
050100
(c
)
S
ce
n
a
ri
o
M
T
D
-2
P
.to
x
=
(0
.10
,0.
30
,0.
50
,0.
60
,0.
70
)
P
ro
po
rt
io
n 
of
 P
a
tie
nt
s 
on
 D
os
es
Proportion
γ=
0.4
γ=
0.5
γ=
0.7
00.51
d5 d4 d3 d2 d1 d0
D
os
e 
Se
le
ct
io
n 
Pe
rc
e
n
ta
ge
Dose selection %
γ=
0.4
γ=
0.5
γ=
0.7
050100
(d
)
S
ce
n
ar
io
M
T
D
-3
P
.to
x
=
(0
.10
,0.
25
,0.
33
,0.
40
,0.
60
)
P
ro
po
rt
io
n 
of
 P
a
tie
nt
s 
on
 D
os
es
Proportion
γ=
0.4
γ=
0.5
γ=
0.7
00.51
d5 d4 d3 d2 d1 d0
D
os
e 
Se
le
ct
io
n 
Pe
rc
e
n
ta
ge
Dose selection %
γ=
0.4
γ=
0.5
γ=
0.7
050100
(e
)
S
ce
n
a
ri
o
M
T
D
-4
P
.to
x
=
(0
.05
,0.
05
,0.
10
,0.
15
,0.
60
)
P
ro
po
rt
io
n 
of
 P
a
tie
nt
s 
on
 D
os
es
Proportion
γ=
0.4
γ=
0.5
γ=
0.7
00.51
d5 d4 d3 d2 d1 d0
D
os
e 
Se
le
ct
io
n 
Pe
rc
e
n
ta
ge
Dose selection %
γ=
0.4
γ=
0.5
γ=
0.7
050100
(f
)
S
ce
n
a
ri
o
M
T
D
-5
P
.to
x
=
(0
.05
,0.
10
,0.
15
,0.
25
,0.
30
)
P
ro
po
rt
io
n 
of
 P
a
tie
nt
s 
on
 D
os
es
Proportion
γ=
0.4
γ=
0.5
γ=
0.7
00.51
d5 d4 d3 d2 d1 d0
D
os
e 
Se
le
ct
io
n 
Pe
rc
e
n
ta
ge
Dose selection %
γ=
0.4
γ=
0.5
γ=
0.7
050100
F
ig
u
re
2
.1
1
:
O
p
er
at
in
g
ch
ar
ac
te
ri
st
ic
s
fo
r
L
o
ss
w
it
h
d
iff
er
en
t
γ
b
as
ed
on
th
e
lo
gi
st
ic
re
g
re
ss
io
n
m
o
d
el
.
In
ea
ch
sc
en
ar
io
,
γ
=
(0
.4
,0
.5
,0
.7
)
fr
om
le
ft
to
ri
gh
t.
T
h
e
to
p
b
ar
s
re
p
re
se
n
t
th
e
av
er
ag
e
p
ro
p
or
ti
on
of
p
at
ie
n
ts
o
n
ea
ch
d
o
se
.
T
h
e
b
ot
to
m
b
a
rs
re
p
re
se
n
t
th
e
M
T
D
se
le
ct
io
n
p
er
ce
n
ta
ge
on
ea
ch
d
os
e.
37
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outperforms the other decision rules, with similar correct MTD selection percent-
ages and conservative patient allocation. For scenarios in which the middle dose
is the true MTD (e.g., MTD-3), CRMr, ODC and Loss achieve similar MTD se-
lection percentages, with ODC assigning more patients to the true MTD. MaxTI
achieves slightly less aggressive MTD selection by assigning more patients to
higher doses. Overall, ODC and MaxTI are recommended for scenarios in which
the middle dose is the true MTD. For scenarios where the higher dose is the true
MTD (e.g., MTD-4 and MTD-5), the four Bayesian decision rules achieve very
similar performances for scenario MTD-4. For scenario MTD-5, CRMr achieves
a slightly higher MTD selection percentage and allocates more patients to dose 5.
ODC and Loss are more conservative in patient allocation, with MTD selection
percentages that are similar to that of CRMr.
2.4.8.2 Comparison based on the logistic regression model
This section summarizes the inter-rule performance based on the Bayesian logistic
regression model for the 6 scenarios illustrated in Figures 2.18 through 2.23. The
modified “3+3” algorithm continues to perform very conservatively compared
to the Bayesian decision rules. For scenarios in which the lower dose is the
true MTD (e.g., MTD-0 to MTD-2), MaxTI performs conservatively. CRMr and
ODC outperform the other decision rules with similar operating characteristics.
For scenarios in which the middle dose is the true MTD (e.g., MTD-3), there is
no significant difference among the four Bayesian decision rules. For ODC, less
information on the higher doses results in a higher MTD selection percentage for
the doses. On the other hand, more toxicity information on the higher doses when
using Loss results in a lower MTD selection percentage for the higher doses. For
scenarios in which the higher dose is the true MTD (e.g., MTD-4 and MTD-5),
Loss outperforms the other decision rules on MTD selection for scenario MTD-4,
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Figure 2.12: Operating characteristics for the 5 rules based on the beta/binomial
model for scenario-MTD0. CRMr is the CRM rule; MaxTI is the rule by Neuen-
schwander et al. . (2008); ODC is the rule by Bekele et al. . (2010); Loss is the
rule by Conaway et al. . (2004); 3+3 is the modified “3+3” algorithm.
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Figure 2.13: Operating characteristics for the 5 rules based on the beta/binomial
model for scenario-MTD1. CRMr is the CRM rule; MaxTI is the rule by Neuen-
schwander et al. . (2008); ODC is the rule by Bekele et al. . (2010); Loss is the
rule by Conaway et al. . (2004); 3+3 is the modified “3+3” algorithm.
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Figure 2.14: Operating characteristics for the 5 rules based on the beta/binomial
model for scenario-MTD2. CRMr is the CRM rule; MaxTI is the rule by Neuen-
schwander et al. . (2008); ODC is the rule by Bekele et al. . (2010); Loss is the
rule by Conaway et al. . (2004); 3+3 is the modified “3+3” algorithm.
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Figure 2.15: Operating characteristics for the 5 rules based on the beta/binomial
model for scenario-MTD3. CRMr is the CRM rule; MaxTI is the rule by Neuen-
schwander et al. . (2008); ODC is the rule by Bekele et al. . (2010); Loss is the
rule by Conaway et al. . (2004); 3+3 is the modified “3+3” algorithm.
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Figure 2.16: Operating characteristics for the 5 rules based on the beta/binomial
model for scenario-MTD4. CRMr is the CRM rule; MaxTI is the rule by Neuen-
schwander et al. . (2008); ODC is the rule by Bekele et al. . (2010); Loss is the
rule by Conaway et al. . (2004); 3+3 is the modified “3+3” algorithm.
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Figure 2.17: Operating characteristics for the 5 rules based on the beta/binomial
model for scenario-MTD5. CRMr is the CRM rule; MaxTI is the rule by Neuen-
schwander et al. . (2008); ODC is the rule by Bekele et al. . (2010); Loss is the
rule by Conaway et al. . (2004); 3+3 is the modified “3+3” algorithm.
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with similar patient allocation. All the Bayesian decision rules perform similarly
in scenario MTD-5.
In this section we compared the five decision rules for dose finding in cancer
trials based on two probability models. The modified “3+3” algorithm performs
very conservatively in patient allocation and MTD selection. The toxicity bound-
aries for MaxTI is chosen to be (0.167, 0.33) to align with those in the “3+3”
algorithm. Simulation results show that with the same toxicity boundaries, the
MaxTI significantly outperforms the modified “3+3” algorithm in patient allo-
cation and MTD selection. All the Bayesian decision rules perform reasonably,
with slight differences in operating characteristics. We identified the appropriate
decision rules to use under specific scenarios.
Compared to the beta/binomial model, the logistic regression model shows
more effect in borrowing strength across doses by performing conservatively in
scenarios in which a lower dose is the MTD, and aggressively in scenarios in which
a higher dose is the MTD.
2.5 Discussion
This chapter has described an investigation of five dose-assignment rules used in
phase I cancer trials. Other than the modified “3+3” algorithm, all Bayesian
decisions are based on the beta/binomial model and the Bayesian logistic regres-
sion model. The Bayesian decision rules summarize the posterior distribution of
toxicity in different ways such that the selected dose’s probability of toxicity is
close enough to the target with appropriate overdose control. Both intra-rule and
inter-rule comparisons were performed based on the 6 scenarios.
Based on the particular priors specified in Section 2.4.2, the modified “3+3”
algorithm performs very conservatively and thus may not be desirable in cancer
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Figure 2.18: Operating characteristics for the 5 rules based on the logistic re-
gression model for scenario-MTD0. CRMr is the CRM rule; MaxTI is the rule by
Neuenschwander et al. . (2008); ODC is the rule by Bekele et al. . (2010); Loss
is the rule by Conaway et al. . (2004); 3+3 is the modified “3+3” algorithm.
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Figure 2.19: Operating characteristics for the 5 rules based on the logistic re-
gression model for scenario-MTD1. CRMr is the CRM rule; MaxTI is the rule by
Neuenschwander et al. . (2008); ODC is the rule by Bekele et al. . (2010); Loss
is the rule by Conaway et al. . (2004); 3+3 is the modified “3+3” algorithm.
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Figure 2.20: Operating characteristics for the 5 rules based on the logistic re-
gression model for scenario-MTD2. CRMr is the CRM rule; MaxTI is the rule by
Neuenschwander et al. . (2008); ODC is the rule by Bekele et al. . (2010); Loss
is the rule by Conaway et al. . (2004); 3+3 is the modified “3+3” algorithm.
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P.tox=(0.10,0.25,0.33,0.40,0.60)
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Figure 2.21: Operating characteristics for the 5 rules based on the logistic re-
gression model for scenario-MTD3. CRMr is the CRM rule; MaxTI is the rule by
Neuenschwander et al. . (2008); ODC is the rule by Bekele et al. . (2010); Loss
is the rule by Conaway et al. . (2004); 3+3 is the modified “3+3” algorithm.
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Figure 2.22: Operating characteristics for the 5 rules based on the logistic re-
gression model for scenario-MTD4. CRMr is the CRM rule; MaxTI is the rule by
Neuenschwander et al. . (2008); ODC is the rule by Bekele et al. . (2010); Loss
is the rule by Conaway et al. . (2004); 3+3 is the modified “3+3” algorithm.
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Figure 2.23: Operating characteristics for the 5 rules based on the logistic re-
gression model for scenario-MTD5. CRMr is the CRM rule; MaxTI is the rule by
Neuenschwander et al. . (2008); ODC is the rule by Bekele et al. . (2010); Loss
is the rule by Conaway et al. . (2004); 3+3 is the modified “3+3” algorithm.
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trials in which a higher toxicity rate can be tolerated. MaxTI, ODC and Loss
are flexible in attaining the desired operating characteristics, depending on how
conservatively or aggressively investigators expect the trial to perform. In con-
trast to the point estimation of toxicity for CRMr, the other Bayesian decision
rules incorporate uncertainty on the probability of toxicity. Information obtained
from historical trials and computer simulations should also be used to direct
the selection of the appropriate dose-assignment rule so that desirable operating
characteristics are achieved.
The next chapter introduces a new design for phase I dose finding in which
the time-to-DLT data is used to allow for the late-onset toxicity to inform dose-
escalation decisions. A time-to-DLT model is proposed for use along with the
MaxTI decision rule introduced in this chapter.
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3A Phase I Dose-Finding Design
Based on a Time-to-DLT Model
3.1 Introduction
Chapter 2 investigated four Bayesian dose-assignment rules for phase I dose-
finding designs in cancer trials, in which the estimation of toxicity is based on
a beta/binomial model or a logistic regression model. Both of these models
account for the occurrence of dose-limiting toxicity (DLT) up to a certain cycle
(e.g., number of DLT occurrences at the end of cycle 1). This chapter introduces
a new Bayesian adaptive design based on a time-to-DLT model, which uses the
available information on all the current patients regarding time to DLT (or time to
censoring) in estimating the probability of DLT at the end of cycle 1. The MaxTI
introduced in Chapter 2 is applied in this new design as the dose-assignment rule.
The content of this chapter represents a collaborative work with Novartis On-
cology under the supervision of Beat Neuenschwander, Lilla Di Scala and Ilona
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Pylvaenaeinen in supporting a series of trials of an investigational drug for lung
cancer and breast cancer. Prior to this study, Thomas Gsponer developed sim-
ulations based on the same time-to-DLT model and a simplified dose-escalation
rule. His work served as a foundation and contributed substantially to the study,
which investigates the feasibility of the combination of a investigational drug with
various chemotherapies based on the safety profile of the combination. The vari-
ous chemotherapies are maintained at a fixed dose throughout the trial, so that
dose-escalation decisions are made with respect to the investigational drug.
The study aims to understand the operating characteristics of the new design
and to determine the toxicity scenarios for which the design is more appropriate
than a logistic regression model. The key issues addressed by the study:
• Provide evidence of the operating characteristics of the new design under
certain scenarios;
• Determine the limitations of the design and how it performs in extreme
scenarios;
• Measure the performance of the time-to-DLT model as compared to the
Bayesian logistic regression model to investigate:
– Whether the time-to-DLT model is more reactive to safety than the
competing model;
– Whether the time-to-DLT model provides more information;
– How the model picks up late-onset toxicity and the impact of this
information on the results;
• Provide evidence regarding the impact of late-onset toxicity on the estima-
tion of the DLT at the end of cycle 1.
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3.2 Time-to-DLT model
Section 3.2 reviews the time-to-DLT model on which the decision rules are
based. Section 3.3 lists the dose-escalation rule for the trial conduct. Section
3.4 provides the operating characteristics of the proposed design compared to the
competing design based on a logistic regression model. Section 3.5 closes this
chapter with a discussion.
3.2 Time-to-DLT model
Assume that for a fixed dose d, the time to DLT follows a Weibull distribution
with the density given by
f(t) = γλtγ−1e−λt
γ
with γ > 0 as the shape parameter and λ > 0 as the scale parameter. Time t
is normalized by the cycle length, which is a technical choice to facilitate prior
tuning and aid in the interpretation. The measure of interest will be the hazard
function at time t, h(t), which, in this context, corresponds to the probability
that a patient experiences a DLT at time t, given that he/she did not experience
a DLT prior to time t. The hazard function is given by
h(t) = γλtγ−1.
We commonly assume that the hazard increases as the dose increases. Define
the scale parameter logλ(d) = log(α) + β ∗ log( d
d∗ ) with β > 0, the log-hazard at
time t for dose d is then given by
log(h(t, d)) = log(α) + β ∗ log( d
d∗
) + log(γ) + (γ − 1)log(t), β > 0
with d∗ being the reference dose.
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Parameter γ determines the shape of the hazard function (monotone, increas-
ing or decreasing), α together with γ determine the hazard at the end of cycle
1 on the reference dose, and β determines the hazard ratio at any time between
two different doses.
Statistical analysis of the model is achieved by a Bayesian approach as this
allows for the proper quantification and combination of uncertainties of both the
model parameters and the derived quantities of interest, such as the risk of DLT
at various dose levels. The likelihood for this model is h(t, d)S(t, d), where S(t, d)
is the survival function at time t for dose d.
The posterior distribution of the model parameters is then translated to the
probability of DLT within the first treatment cycle (0, 1), on which the dose-
escalation decision will be based:
P (tDLT < 1|d) = 1− S(1, d).
The posterior distribution of the cycle-1 DLT rate will be summarized using
the following intervals:
• [0, 0.20) underdosing toxicity;
• [0.20, 0.35) target toxicity;
• [0.35, 0.60) excessive toxicity;
• [0.60, 1] unacceptable toxicity.
The choice of the above cut-off points does not depend on the model but
rather needs to be discussed and selected on a trial-by-trial basis.
The priors
An uninformative bivariate normal prior for the vector [log(α), log(β)], and an
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uninformative normal prior for log(γ), are used in the simulation study. The pro-
cedure for deriving the prior values of the model parameters is based on the prior
assumptions of the probability of DLT within the first treatment cycle, as shown
in Table 3.1. Hereafter this quantity will be referred to as the end-of-cycle-1 DLT
rate.
Table 3.1: Prior quantiles for the end-of-cycle-1 DLT rate
2.5%QNT 50%QNT 97.5%QNT
2.5mg/day 0.01 0.10 0.67
5mg/day 0.02 0.17 0.80
10mg/day 0.03 0.26 0.97
The parameters derived for the bivariate normal distribution of [log(α), log(β)]
are given in Table 3.2. The parameters for the normal distribution for log(γ) are
selected to be Normal(0, 0.20). Figure 3.1 shows the prior probability of cycle-
1 DLT in each toxicity interval for each dose as a consequence of the priors
of the model parameters. The dose-escalation decision is based on each dose’s
probability in the target toxicity interval (overdose control criteria are introduced
in Section 3.3.1).
Table 3.2: Parameters for bivariate normal distribution
E(log(α)) E(log(β)) std log(α) std log(β)
-1.74 -0.54 1.17 0.75
Posterior sampling
This study implements a direct sampling mechanism for determining the pos-
terior cycle-1 DLT rate (Gelman et al. 2004). The method approximates the
distribution of a continuous parameter as a discrete distribution on a grid of
points. For low-dimensional likelihood functions, this method can significantly
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Figure 3.1: Prior distribution of the end-of-cycle-1 DLT rate for each dose as a con-
sequence of the priors of the model parameters. The four toxicity intervals are tox1:
underdosing [0, 0.20), tox2: targeted [0.20, 0.35), tox3: excessive [0.35, 0.60) and tox4:
unacceptable [0.60, 1.00].
improve computational time as compared to Markov chain simulations. A brief
description of this method is provided hereafter.
For the simplest discrete approximation, compute the target density, p(θ|y),
at a set of evenly spaced values θ1, · · · , θN that cover a broad range of the param-
eter space for θ, then approximate the continuous p(θ|y) by the discrete density
at θ1, · · · , θN with probabilities p(θi|y)∑N
i=1 p(θi|y)
. Once the grid of density values is com-
puted, a random draw from p(θ|y) is obtained by drawing a random sample from
the uniform distribution on [0,1], then transformed by the inverse cdf. method
to obtain a sample from the discrete approximation (Gelman et al. 2004).
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3.3 Study Design
3.3.1 Decision rule
The primary end point of this study is the end-of-cycle-1 DLT rate, expressed for
each dose level in terms of the cycle-1 DLT rate that falls within the predefined
toxicity intervals. The trials covered by this simulation study could use up to
three doses in a daily regimen of the investigational drug, namely 2.5 mg/day,
5 mg/day and 10 mg/day in a 21-day cycle. In addition, for the purpose of
evaluating model performance, the simulations will also investigate five doses in
a daily regimen, with the addition of 1mg/day and 7.5mg/day. In order to better
categorize the operating characteristics, a dummy dose (0mg) will be imposed in
cases in which the first dose is found to be too toxic. The model will be able to
recommend the dummy dose, thereby forcing the trial to stop immediately.
The study design uses the posterior end-of-cycle-1 DLT rate per dose level,
summarized in the toxicity intervals given in Figure 3.1, to identify the feasible
dose level at which the model can safely assign the succeeding patient cohort. A
dose level is defined as feasible with respect to the rate of DLTs if it satisfies the
following properties:
1. It maximizes the probability of the end-of-cycle-1 DLT rate within the target
toxicity interval; and
2. It corresponds to a less than 25% probability of the end-of-cycle-1 DTL rate
falling within the combination of the excessive and unacceptable toxicity
intervals.
Condition (2) will be referred to as the overdose control criteria, i.e., criteria that
controls the risk of excessive and unacceptable toxicity such that it remains below
a specified threshold.
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3.3.2 Trial conduct
Figure 3.2 illustrates the conduct of the design. At every decision point the
model identifies the dose level that is currently the most feasible, by evaluating
the end-of-cycle-1 DLT rate within the predefined toxicity interval. This dose
level is then adjusted by the safety-related issue (i.e., no skipping a dose when
escalating). The next dose level is then recommended for the next cohort of
patients. This procedure is repeated until one of the prespecified stopping rules
is satisfied. The trials are conducted as follows:
• Simulation starts at the time of the first patient’s first visit (FPFV). Pa-
tients are recruited at a specific rate, which is exponentially distributed
with a mean of 1/7 per day. Patient accrual is suspended after the 6th
patient has been enrolled. The model is first evaluated when all of the first
six patients have finished cycle 1 (or experienced DLT within cycle 1). Re-
cruitment continues thereafter without accrual suspension. Dose-escalation
decisions will be made when a cycle-1 DLT happens, or two months after
the last decision time point.
• If the model recommends a dose that is more than one level higher than the
current dose, only the next higher dose will be assigned to the next patient
cohort.
• The trial will be stopped for successfully declaring the MTD if all of the
following criteria are satisfied:
– The corresponding dose is found to be feasible according to the criteria
given in Section 3.3.1;
– At least 6 patients on this dose have finished cycle 1 (or experienced
DLT);
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– At least 12 patients in the trial have finished cycle 1 (or experienced
DLT).
• The trial will be stopped for failure to declare the MTD if any of the fol-
lowing events occur before the MTD is declared:
– The dummy dose (0mg) is recommended by the model;
– The maximum number of patients in the trial is reached;
– The maximum trial length is reached.
A graphical presentation of a simulated trial based on the particular priors
specified in Section 3.2 is displayed in Figure 3.3. The middle plot shows the
patient accrual from the first patient’s first visit and the dose assignment. The
columns on the right side list the time to DLT (or time to censoring) for each
patient. The plot at the bottom of the figure marks the dose-escalation points
and the total number of patients assigned to each dose up to that point. The
upper panel of bar graphs shows the probability of toxicity within the predefined
toxicity intervals for each dose. The decision of dose escalation is based on these
bar graphs. The true MTD in this simulated trial is 10mg. The trial successfully
declared 10mg as the MTD after 238 days, with a total of 21 patients enrolled in
the trial. Twelve patients out of the 21 enrolled in the trial were assigned to the
true MTD, 3 of which experienced cycle 1 DLT.
3.4 Simulation
3.4.1 Scenarios
The underlying time-to-DLT model from which the events are simulated is a
Weibull two-parameter model. The parameters of the Weibull time-to-DLT model
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Figure 3.2: Trial conduct using the proposed phase-I dose-finding design based
on the time-to-DLT model.
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for the scenarios are defined by fixing the probability of DLT on the reference
dose at the end of cycle 1 (pd∗) and at the end of cycle 2 (pe∗). The probabilities
pd∗ and pe∗ are used to determine α and γ :
α = −log(1− pd∗),
and
γ = log[−log(1− pe∗)]− log(α)/log(2).
The parameters of the simulation scenarios are shown in Table 3.3. Within
each of the three groups, the parameters are selected such that each scenario has
the same end-of-cycle-1 DLT rate on the reference dose (5mg) with increasing
hazard (IH), constant hazard (CH) and decreasing hazard (DH) over cycles. Pa-
rameter β is similar across the scenarios. Plots of the probability of DLT over
the treatment cycles for all scenarios are shown in Figure 3.4. For each scenario,
the true MTD’s probability of DLT at the end of cycle 1 falls within the targeted
toxicity interval. The curvature of each plot is determined by the hazard rate.
3.4.2 Operating characteristics
In order to better investigate the performance of the time-to-DLT model, a com-
peting model is selected for comparison: the Bayesian logistic regression model
introduced in Chapter 2, which uses binary toxicity data and requires full obser-
vation of each patient cohort. That model bases dose-escalation decisions on the
posterior estimation of the cycle-1 DLT rate, following the same prior probabil-
ities of toxicity that were outlined in Section 3.2 and the same rules that were
outlined in Section 3.3. A metric we use to evaluate model performance is the
percentage of trials in which the true MTD is successfully declared, and the av-
erage number of patients assigned to each dose. Table 3.4 illustrates the primary
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Figure 3.4: Dose-toxicity plots for three groups of scenarios. IH indicates increasing
hazard, CH indicates constant hazard, and DH indicates decreasing hazard. The title of
each plot indicates the true MTD, e.g., SC5-CH means that the true MTD is 5mg with
constant toxicity hazard over the treatment cycles.
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Table 3.3: Scenarios defined by the time-to-DLT model.
input parameters for the models and trial conduct. The maximum number of
patients enrolled in each trial is limited to 100 for simulation purposes only. The
simulated trials rarely reach this upper limit for all scenarios.
Figures 3.5 to 3.7 illustrate the operating characteristics of the designs based
on the time-to-DLT model vs. the logistic regression model. Doses of 2.5mg,
5mg and 10mg are evaluated. Patients are followed for 6 cycles, 3 cycles and 1
cycle, respectively, for the design based on the time-to-DLT model. Patients are
always followed for 1 cycle for the logistic regression design. Trials always start
at the lowest dose, which is 2.5mg in these scenarios. The top sections of the
bars represent the average number of patients assigned to each dose. The bottom
sections of the bars represent the MTD selection percentage for each dose. Each
bar group represents the results from one group of scenarios in Table 3.3, with
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Table 3.4: Key design parameters based on the time-to-DLT model and the
logistic regression model.
the first 3 bars (from the left) representing the results based on the time-to-
DLT model for scenarios with increasing hazard (IH), constant hazard (CH) and
decreasing hazard (DH). The 4th bars (from the left) are the results based on the
logistic regression (LR) model.
There is no significant difference in the operating characteristics based on
the time-to-DLT model for all the scenarios with 6-cycle follow-up or 3-cycle
follow-up. For scenarios with increasing toxicity hazard, the trials based on the
time-to-DLT model perform more conservatively, with longer follow-up (shown
in Figure 3.5 and Figure 3.6). This is because more late-onset toxicities beyond
cycle 1 contribute to a higher estimation of the DLT rate at the end of cycle
1. For scenarios with decreasing toxicity hazard and with longer follow-up, the
trials based on the time-to-DLT model perform less conservatively because fewer
late-onset toxicities contribute to a lower estimation of the DLT rate at the end of
cycle 1. For the trials with 1-cycle follow-up (in Figure 3.7), the MTD selection
percentage shows a different trend compared with those for trials with longer
follow-up: the trials based on the time-to-DLT model perform less conservatively
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for scenarios with increasing toxicity hazard because fewer early-onset toxicities
contribute to a lower estimation of the DLT rate at the end of cycle 1. By
contrast, the trials based on the time-to-DLT model perform more conservatively
for scenarios with decreasing toxicity hazard because more early-onset toxicities
contribute to a higher estimation of the DLT rate at the end of cycle 1.
Based on these prespecified parameters for trial conduct (e.g., accrual rate,
decision points, etc.), the results indicate that a 3-cycle follow-up is appropriate
for the design based on the time-to-DLT model. Thus, the estimation of the
DLT rate at the end of cycle 1 combines more toxicity information from multiple
cycles. The new design shows more safety benefits for trials in which more late-
onset toxicities are expected. As a trade-off, the new design requires more patients
on average.
Figures 3.8 to 3.10 illustrate the operating characteristics of the time-to-DLT
model and the logistic regression model for which the evaluated doses are 1mg,
2.5mg, 5mg, 7.5mg and 10mg, using the scenarios that were defined in Table 3.3.
Although the lowest dose for model input is 1mg, the starting dose continues to
be 2.5mg. There is no significant difference in the operating characteristics based
on the time-to-DLT model with 6-cycle follow-up or 3-cycle follow-up. The true
toxicity hazard shape continues to contribute to the difference in patient alloca-
tion and MTD selection based on the time-to-DLT model. With the addition of
a lower dose of 1mg, trials are stopped less for failure for the scenario group in
which the true MTD is 2.5mg. Overall, when compared to the logistic regres-
sion model, the time-to-DLT model yields higher MTD selection percentages and
requires more patients on average.
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Figure 3.5: Operating characteristics of the design based on the time-to-DLT model
with 6-cycle follow-up, and of the logistic regression model for 3 groups of MTD scenarios.
The top sections of the bars represent the average number of patients on each dose; the
bottom sections of the bars represent the MTD selection percentage for each dose. Within
each group, the first 3 bars (from the left) are the results based on the time-to-DLT model
with 3 different hazard shape scenarios; the 4th bars (from the left) are the results based
on the logistic regression model.
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Figure 3.6: Operating characteristics of the design based on the time-to-DLT model
with 3-cycle follow-up, and of the logistic regression model for 3 groups of MTD scenarios.
The top sections of the bars represent the average number of patients on each dose; the
bottom sections of the bars represent the MTD selection percentage for each dose. Within
each group, the first 3 bars (from the left) are the results based on the time-to-DLT model
with 3 different hazard shape scenarios; the 4th bars (from the left) are the results based
on the logistic regression model.
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Figure 3.7: Operating characteristics of the design based on the time-to-DLT model
with 1-cycle follow-up, and of the logistic regression model for 3 groups of MTD scenarios.
The top sections of the bars represent the average number of patients on each dose; the
bottom sections of the bars represent the MTD selection percentage for each dose. Within
each group, the first 3 bars (from the left) are the results based on the time-to-DLT model
with 3 different hazard shape scenarios; the 4th bars (from the left) are the results based
on the logistic regression model.
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Figure 3.8: Operating characteristics of the design based on the time-to-DLT model
with 6-cycle follow-up, and of the logistic regression model for 3 groups of MTD scenarios.
The top sections of the bars represent the average number of patients on each dose; the
bottom sections of the bars represent the MTD selection percentage for each dose. Within
each group, the first 3 bars (from the left) are the results based on the time-to-DLT model
with 3 different hazard shape scenarios; the 4th bars (from the left) are the results based
on the logistic regression model.
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Figure 3.9: Operating characteristics of the design based on the time-to-DLT model
with 3-cycle follow-up, and of the logistic regression model for 3 groups of MTD scenarios.
The top sections of the bars represent the average number of patients on each dose; the
bottom sections of the bars represent the MTD selection percentage for each dose. Within
each group, the first 3 bars (from the left) are the results based on the time-to-DLT model
with 3 different hazard shape scenarios; the 4th bars (from the left) are the results based
on the logistic regression model.
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Figure 3.10: Operating characteristics of the design based on the time-to-DLT model
with 1-cycle follow-up, and of the logistic regression model for 3 groups of MTD scenarios.
The top sections of the bars represent the average number of patients on each dose; the
bottom sections of the bars represent the MTD selection percentage for each dose. Within
each group, the first 3 bars (from the left) are the results based on the time-to-DLT model
with 3 different hazard shape scenarios; the 4th bars (from the left) are the results based
on the logistic regression model.
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3.5 Discussion
This chapter introduced a phase I dose-finding design based on a time-to-DLT
model. Instead of using the binary DLT data within treatment cycle 1, the
time-to-DLT model associates time with toxicity information in estimating the
probability of DLT at the end of cycle 1. Dose-escalation decisions are made
whenever a cycle-1 DLT occurs, or 2 months after the previous decision-making
point. The new model allows a DLT beyond cycle 1 to inform the dose-escalation
decision. The time-to-DLT model distinguishes scenarios in which the same end-
of-cycle-1 DLT rate is achieved by different hazard shapes, a differentiation that
is not captured by the logistic regression model. As a trade-off, a trial based on
the time-to-DLT model requires a slightly higher patient accrual to declare the
MTD.
The time-associated toxicity information in this design is dichotomized based
on its dose-limiting characteristics. However, toxicities in cancer trials are usually
categorized into severity levels, which are not of equal importance and do not
occur independently. The next chapter introduces a new design for phase I dose
finding in which the toxicity is categorized by severity levels and transitions over
time. The new design allows partial toxicity information to contribute to dose-
escalation decisions. A new discrete-time multi-state model is proposed for use
along with the ODC decision rule introduced in Chapter 1.
Unlike the traditional logistic regression model which can only estimate the
DLT rate at the end of cycle 1 based on patients’ binary toxicity data within
cycle 1, the time-to-DLT model introduced in this chapter can also estimate
the DLT rate for cycles that occur after cycle 1. To better characterize toxicity
information for dose-escalation decisions, we can combine the toxicity information
across multiple cycles to inform dose-escalation decisions. One approach is to
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assign a toxicity score to correspond with each treatment cycle such that it reflects
the relative importance of the DLT within that cycle. The posterior probabilities
of DLT for the multiple cycles are then integrated by the toxicity scores into an
average toxicity score (ATS). Dose-escalation decisions are then based on the ATS.
The ATS approach is introduced in the next chapter as a manner of integrating
the probability of each toxicity level as the maximum for dose-escalation decisions.
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4Adaptive Dose Finding in Phase
I Cancer Trials Based on a
Discrete-Time Multi-State Model
Chapter 2 investigated four Bayesian dose-assignment rules for phase I dose-
finding designs in cancer trials in which decisions are made based on the pos-
terior probability of toxicity. One of the rules, MaxTI, was used in the dose-
finding design in Chapter 3, which applied a time-to-DLT model to estimate the
dose-limiting toxicity (DLT) rate at the end of cycle 1. None of the four dose-
assignment rules or the time-to-DLT model considers toxicity severity levels and
inter-level transitions. This chapter introduces a phase I dose-finding design in
which (i) toxicity is categorized into multiple severity levels, and (ii) patients’
toxicity states are measured periodically according to the treatment cycles. As
the model allows patients’ early toxicity states to inform dose escalation, there is
no requirement of accrual suspension between patient cohorts.
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This chapter views the problem in a different way and is not a special case of
any other chapters. We start the chapter with a description of the discrete-time
multi-state model, followed by the dose-assignment rule. We then introduce a
fully-evaluated model proposed by Bekele et al. (2010) as a comparison. We
perform simulations to explore the operating characteristics of the two designs,
and close the chapter with a brief discussion.
4.1 Introduction
Standard phase I trials dichotomize toxicity based on whether the toxicity is dose
limiting. For example, if grade 4 fatigue is a dose-limiting toxicity, while fatigue
of grade 1, 2, and 3 are considered not dose limiting, then grade 1 fatigue and
grade 3 fatigue are treated identically. These approaches are designed to address
early toxicity of a sufficiently high level. However, due to the ethical requirement
to limit the number of patients in the trial who experience toxicity, the above
methods discard useful information and lead to other problems. First, if a drug
causes delayed toxicity and the trial’s accrual rate is high, many patients may
be treated at overly toxic doses before clinicians are aware that any patients
have experienced toxicity. Second, different categories of toxicity are not of equal
importance and do not occur independently. If several categories of toxicity are
likely to occur, a model describing the transitions from one toxicity grade to
another is needed.
De Moor et al. (1996) proposed a modification of the standard continual
reassessment method (CRM) in which ordinal toxicity grade information is in-
corporated into the estimation of the maximum tolerated dose (MTD) using a
cumulative logit model. The model considers that the increasingly severe tox-
icity grades associate with one another in a nesting manner, and confines the
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dose-toxicity curves of each toxicity grade to like forms. Yuan et al. (2007) pro-
posed a Bayesian quasi-likelihood approach based on CRM for multiple toxicity
grades. Bekele and Thall (2004) developed a Bayesian method for dose finding
based on a vector of correlated, ordinal-valued toxicities with severity levels that
varied with the dose. Bekele et al. (2010) considered possible outcomes of tox-
icity with differing degrees of severity, defined appropriate scores for the degree
of severity, and characterized the overall toxicity using an average toxicity score
(ATS) parameter. These methods go beyond the conventional approaches and
allow toxicity levels to inform dose-escalation decisions. In addition to controls
for early-onset toxicity, clinical trials must address controls for late-onset toxicity.
To better characterize toxicity severity levels and inter-level transitions, we
propose a phase I dose-finding design based on a discrete-time multi-state (DTMS)
model. We use the term “discrete-time” to address multiple decision time points.
We use “multi-state” to address multiple toxicity severity levels. The methodol-
ogy is motivated by our desire to address several limitations arising from the use
of established methods. First, this method accounts for the fact that toxicities
can be clinically characterized over a distribution of severity levels. In addition,
the method allows early lower severity levels to inform dose-escalation decisions.
Last, the method allows for the enrollment of the next patient or small cohort of
patients into the trial before the previous patient or cohort has been completely
followed. This is possible because the Bayesian model allows us to account for
uncertainty while applying sequentially adaptive decision rules.
Table 4.1 lists the key factors that highlight the proposed design compared
with a fully-evaluated design by Bekele et al. (2010) and other phase I dose-
finding designs that were introduced in Chapter 2. This chapter focuses on the
first two designs that categorize toxicity into multiple severity levels.
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Table 4.1: Phase I dose-finding methods and design factors
Design Factors DTMS Design Fully-Evaluated Design 3+3 Designs CRMr/MaxTI/ODC/Loss
Multi-level toxicity? Yes Yes No No
Accrual suspended between cohorts? No Yes Yes Yes
Cycles during which toxicity assessed Multiple 1 1 1
Cohort size specified No No Yes No
Target toxicity rate Flexible Flexible 0.33 Flexible
4.2 Bayesian discrete-time multi-state model
Multi-state models are extensions of competing risks models, which incorporate
an initial state and several mutually-exclusive absorbing states. In our design
problem, toxicity is characterized by multiple severity levels, but not classified as
initial or final states. We classify our model as a multi-state model that considers
the transitions between multiple toxicity severity levels. In practice, the multi-
state model is often considered to be a Markov model. A general interpretation
of the Markov trait is that our predictions depend on history only through the
present time. Applied to our multi-state model, this trait indicates that, given a
patient’s history and the present toxicity level, the designation of the next toxicity
level, as far as how much and when, depends on only the present toxicity level.
In addition to the Markov properties stated above, we propose a discrete-time
multi-state model, which assumes a specific transition probability matrix for each
time interval.
We define a sequence of time points such that 0 = t0 < t1 < · · · < tJ < ∞,
where (tj−1, tj] is expressed as the time interval j and (t0, tJ ] is the patients’ entire
assessment window with J intervals. Let Yj take on one of K possible values
(1, · · · , K), where Yj = k means that the kth level of toxicity is observed during
period j. Define the transition probability, i.e., the probability of transitioning
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from a toxicity level k during the time interval j− 1 to a level k′ during the time
interval j, as
pj,k,k′ = Pr(Yj = k
′ | Yj−1 = k).
For the purpose of modeling toxicity, we assume that
1) If k = K, then pj,k,k′ = Pr(Yj = K | Yj−1 = K) = 1, which implies that the
highest toxicity level K is irreversible. In cancer trials, toxicity level K usually
indicates treatment cessation.
2) If k < K, then pj,k,k′ = Pr(Yj = k
′ | Yj−1 = k) > 0, which implies that other
than the highest level, a toxicity level can change bi-directionally.
For example, we categorize toxicity into 5 severity levels (K = 5) where
level 1 indicates no toxicity or minimum toxicity, and level 5 indicates treatment
cessation. All patients start at toxicity level 1 prior to entry into the trial. A
patient receives a treatment on day 1 and is followed for 6 weeks (J = 6). Suppose
he/she develops a level 3 toxicity during the first week. The toxicity increases to
level 4 during the second week and drops back to level 3 during the third week.
The toxicity then drops to level 2 during the fourth week and stays at level 2 for
the remaining weeks. The accumulating data appear as (Y1 = 3, Y2 = 4, Y3 =
3, Y4 = Y5 = Y6 = 2). Table 4.2 illustrates the observed toxicity level for each week
and its contribution to the likelihood through pj,k,k′ . It is also possible that due to
the pathological nature of a certain drug or treatment, patients are more likely to
develop late onset toxicity, e.g., (Y1 = 1, Y2 = 1, Y3 = 2, Y4 = 3, Y5 = 4, Y6 = 4).
For trials in which patients are scheduled to receive a treatment periodically, e.g.,
once every week for 6 weeks, it is more likely that the observed toxicity level will
jump up and down over time, e.g., (Y1 = 3, Y2 = 2, Y3 = 3, Y4 = 2, Y5 = 3, Y6 = 2).
Let yi,j ∈ [1, ..., K], (i = 1, ..., n), denote the toxicity state of the ith patient
during time period j. Let yi = (yi,1, ..., yi,J) represent the sequence of toxicity
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Table 4.2: One patient’s contribution to the probability model through pj,k,k′ .
Week 0 1 2 3 4 5 6
Toxicity level 1 3 4 3 2 2 2
Contribution p1,1,3 p2,3,4 p3,4,3 p4,3,2 p5,2,2 p6,2,2
states observed for the ith patient over the [1, · · · , J ] periods during which data
are available for this patient. We use a discrete-time multi-state model and
assume that transitions from a given toxicity level are independent of the history
of the process prior to entry into that level. The general form of the contribution
of each patient to the likelihood is as follows:
L(yi) =
J∏
j=1
K∏
k=1
K∏
k′=1
p
I(yi,j−1=k)I(yi,j=k′)
j,k,k′
Let vector Pj,k = (pj,k,1, pj,k,2, · · · , pj,k,K). A priori, Pj,k,k′ is distributed as
Pj,k ∼ Dirichlet(αj,k,1, αj,k,2, · · · , αj,k,K).
A Dirichlet distribution is the multivariate generalization of the beta distribu-
tion, and conjugate prior of the multinomial distribution in Bayesian statistics.
In our study, its probability density function returns to the form in which the
probabilities of K competing events are pj,k,k′ , given that each event has been
observed αj,k,k′ − 1 times.
Define nj,k,k′ as the number of patients during time interval j who were initially
in toxicity level k and transitioned to level k′ with nj,k,k′ =
∑n
i=1 I(Yi,j−1 =
k)I(Yi,j = k
′), where n is the total number of patients currently in the trial. The
model assumes that
(nj,k,1, nj,k,2, · · · , nj,k,K) ∼Multinomial(
K∑
k′=1
nj,k,k′ , Pj,k).
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Since the multinomial and Dirichlet distributions are conjugate, the posterior
distribution of Pj,k is
Pj,k | Data ∼ Dirichlet(αj,k,1 + nj,k,1, αj,k,2 + nj,k,2, · · · , αj,k,K + nj,k,K).
Denote Pj as a matrix with transition probabilities pj,k,k′ . In our study we
define toxicity level 1 as no toxicity or minimum toxicity and assume that all
patients start with toxicity level 1, so that P1 is a 1 ×K vector with transition
probabilities p1,1,k′ , and Pj is aK×K matrix for j > 1 with transition probabilities
pj,k,k′ .
The posterior distribution of the transition matrices Pj are updated as new
data accumulates. These transition probabilities serve as the basis, upon which
decisions are made.
The above multinomial/Dirichlet model combines the prior information and
the current observed data into Pj. In addition to the model described above,
we borrow an idea from Bekele et al. (2010, to define an average toxicity score
(ATS). We describe this quantity in more detail below. There remains a need
to integrate these matrices into a quantity that reflects the toxicity severity for
the patient’s entire assessment window. We address this need using an idea
borrowed from Bekele et al. (2010), who defined appropriate scores for these
toxicity levels and characterized the overall toxicity using an average toxicity
score (ATS) parameter.
Define pik as the probability of observing toxicity level k as the maximum
toxicity level within the patient assessment window. To calculate pik from Pj, we
first define Qk as the probability of observing less than or equal to level k toxicity
within the assessment window. Qk is expressed as
Qk = P (max{Yj} ≤ k|data) = {
J∏
j=1
Pj[1 : k]}{(1, · · · , 1)k}T ,
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where {(1, · · · , 1)k}T is a k-vector of ones, Pj[1 : k] represents the first 1× k sub-
vector from Pj for j = 1, and Pj[1 : k] represents the upper-left (k×k) sub-matrix
from Pj for j > 1.
J∏
j=1
Pj[1 : k] is a 1×k vector, which represents the probability of
observing level (1, · · · , k) toxicity at the end of patient assessment window without
observing greater than level k toxicity during the entire assessment window. Qk
is the sum of the elements of
J∏
j=1
Pj[1 : k] by multiplying the k-vector of ones. We
can then express pik as
pik =
{
Qk if k = 1
Qk −Qk−1 if k ≥ 2
The above process combines transition matrices from all time intervals into
pik, which reflects the overall probability that toxicity level k is the maximum.
By applying an approach that is similar to that of Bekele and Thall (2004),
we can integrate the influence of each toxicity severity level into the decision
making.Bekele and Thall (2004) depicted the clinical importance of each toxicity
severity level by assigning weights to each level. Following this approach, we
obtain from the clinicians a score for each toxicity severity level. Let wk be the
score obtained for toxicity severity level k, and denote w= (w1, . . . , wK), where
0 = w1 < w2 < . . . < wK . Increasing severity of toxicity is represented by
increasing score values.
To measure the overall toxicity for each dose, we define the average toxicity
score (ATS) at each dose as
ATS =
K∑
k=1
wk · pik (4.1)
The toxicity score wk represents the investigator’s expert opinion and is limited
to positive values that are contingent upon the monotonicity constraint. In our
study, we scale the toxicity score between 0 and 1.
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The above process combines the transition probability matrices so as to repre-
sent the toxicity severity for the entire patient assessment window. An underlying
assumption in dose-finding trials is that toxicity increases with an increasing dose;
however, the ATS may not be isotonically ordered across doses. To address that
issue, we take an isotonic regression approach similar to that of Ji et al. (2007a),
and apply the pooled adjacent violators algorithm (PAVA, robertson et al. 1988) to
borrow information across doses. To carry out the Bayesian isotonic transforma-
tion, we obtain posterior samples of the ATS for each dose from equation 4.1 and
apply the PAVA to the posterior sample vectors of the ATS . Denote ATSd as the
order-restricted ATS for dose d. The algorithm guarantees that ATSdj ≥ ATSdi
for dose levels dj > di. De Leeuw et al. (2009) provided a general framework
for isotonic regression, as well as implementation software. Hereafter, we will use
ATS as an abbreviation of the order-restricted ATS.
The above integration and isotonic regression combine all the transition prob-
abilities into an order-restricted average toxicity score between 0 and 1. The ATS
can then be treated as the probability of overall toxicity and serve in that manner
for the dose-assignment rule.
4.3 Dose-assignment rule
The maximum tolerated dose (MTD) is defined as the highest dose with ATSd
closest to and no larger than a target ATS∗. In this section we introduce a dose-
escalation rule based on the posterior probability that ATSd is greater than the
target ATS∗. This rule is similar to the overdose control rule ODC described in
Chapter 2.
The dose-escalation decision-making approach we propose borrows an idea
from Bekele et al. (2010), who based dose-escalation decisions on the posterior
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probabilities ξd = Pr(ATSd > ATS
∗|data). We first partition the unit interval
into three subintervals by the cutoff values 0 < ξ < ξ < 1 and define that toxicity
at dose d is inconsequential if ξd < ξ, permissible if ξ ≤ ξd ≤ ξ, and prohibitive if
ξd > ξ. The selection of the cutoff values reflects the investigator’s preference for
a more aggressive or more guarded treatment approach. Information obtained
from computer simulation should also be used to achieve desirable operating
characteristics.
Given the above definitions, we describe a dose-finding rule:
• Treat the first cohort of patients at the lowest dose.
• Whenever a new cohort of patients is recruited to the trial, reassess for
toxicity with the currently available data and for dose-assignment decisions
to de-escalate, stay, escalate or stop.
• If the current dose evinces inconsequential toxicity, then escalate to the
next higher dose. Stay at the current dose if the next higher dose evinces
prohibitive toxicity.
• If the current dose evinces permissible toxicity, then stay at the current
dose.
• If the current dose i evinces prohibitive toxicity and i > 1, then de-escalate
to the highest dose less than i that is not prohibitively toxic. If i = 1 or all
doses evince prohibitive toxicity, then stop the trial and declare failure in
finding the MTD.
• Upon the trial’s conclusion, select a dose with either inconsequential or
permissible toxicity that has a posterior mean closest to the target pi∗.
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4.4 An alternative fully-evaluated model as a
comparison
An alternative approach to modeling toxicity severity levels is to directly model
the maximum observed toxicity level within the entire patient assessment win-
dow for each dose. The individual probabilities of each toxicity level being the
maximum are then combined into an average toxicity score (ATS) as described
above for dose escalation. The method requires the current cohort of patients to
be completely observed for model evaluation.
Let yi be the maximum observed toxicity level for patient i, where Yi = k
means that the kth level of toxicity is observed as the maximum. Recall that
pik is the probability of observing toxicity level k as the maximum within the
patient assessment window. The general form of the contribution to the likelihood
attributed to each patient is as follows:
L(yi) =
K∏
k=1
pi
I(yi=k)
k
Let vector pi = (pi1, · · · , piK). A priori, pi is distributed as
pi ∼ Dirichlet(β1, β2, · · · , βK).
Define nk =
∑n
i=1 I(Yi = k). Since the multinomial and Dirichlet distributions
are conjugate, the posterior distribution of pi is
pi | Data ∼ Dirichlet(β1 + n1, · · · , βK + nK).
Once we deliver the posterior distribution for pi, we apply the same procedure
for averaging pi into ATS and the isotonic regression on the posterior ATS for
dose assignment and trial termination.
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4.5 Simulation comparing the proposed design
with the alternative
4.5.1 Scenarios
In investigating the operating characteristics of this design, the metrics we use
to evaluate the design performance includes (i) the percentage of the trials in
which the true MTD is successfully declared, (ii) the average trial length, and
(iii) the average number of patients assigned to each dose. Considerations we use
to evaluate operating characteristics are contained within the paragraphs that
follow.
In the simulation study, we let the accrual rate r follow an exponential dis-
tribution with the mean accrual rate of 0.5 or 1 patient per week. Patients are
assigned to one of three doses and followed for 6 weeks (J = 6). The first cohort
of patients always receives the lowest dose. There are 5 toxicity severity levels
(K = 5). The elicited score for each toxicity level is w1 = 0, w2 = 0.25, w3 = 0.5,
w4 = 0.75, w5 = 1. The maximum sample size is 30. The trial will stop early
for toxicity when data indicate that the lowest dose is too toxic. For trials that
are not stopped early, the last evaluation point occurs when all 30 patients have
finished the trial.
For the purpose of generating scenarios, we define the true transition prob-
ability matrix Pj through τ (0 ≤ τ ≤ 1). Table 4.3 shows the structure of Pj
determined by τ . The rationale is that the current toxicity level at time j is more
likely to stay closer to the previous level at time j − 1. This is a huge reduction
in dimensionality from 16 to 1, which allows us to show the relationship between
τ and the ATS through a graph. Figure 4.1 illustrates the negative correlation
between τ and the ATS. We generate scenarios by specifying individual τ for
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each Pj to achieve the desired toxicity hazard shape over the time intervals while
controlling the true ATS within the entire assessment window.
Table 4.3: Structure of the transition probability matrix
pj,k,k′ Tox1 Tox2 Tox3 Tox4 Tox5
Tox1 τ 12 (1− τ) 14 (1− τ) 16 (1− τ) 112 (1− τ)
Tox2 13 (1− 0.8τ) 0.8τ 13 (1− 0.8τ) 14 (1− 0.8τ) 112 (1− 0.8τ)
Tox3 16 (1− 0.6τ) 13 (1− 0.6τ) 0.6τ 13 (1− 0.6τ) 16 (1− 0.6τ)
Tox4 112 (1− 0.4τ) 14 (1− 0.4τ) 13 (1− 0.4τ) 0.4τ 13 (1− 0.4τ)
Tox5 0 0 0 0 1
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Figure 4.1: True value of ATS determined by τ
For each dose, we let the Dirichlet parameters (αj,k,1, αj,k,2, · · · , αj,k,K) have
the same structure as shown in Table 4.3, so that the priors for the ATSd are
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(0.14, 0.15, 0.18) and the effective sample size is equivalent to one.
We first divide the scenarios into two groups. For the first group, the ATSd1
is fixed at 0.13 and the ATSd3 is fixed at 0.53. The ATSd2 changes from 0.13
to 0.53 with a total of 11 scenarios. For the second group, the ATSd1 is fixed at
0.05 and the ATSd2 is fixed at 0.13. The ATSd3 changes from 0.13 to 0.53 with
a total of 11 scenarios.
Within each group of scenarios, the toxicity hazard is either constant(a),
decreasing(b), increasing(c) or scalloping(d) over the time intervals. This is
achieved by specifying the values of τ in the transition probability matrices Pj
such that the corresponding toxicity hazard has the aforementioned shape with
the pre-specified ATS.
4.5.2 Sample trial conduct based on the fully-evaluated
design and the DTMS design
Figure 4.2 shows the plot of a simulated trial based on (a) the fully-evaluated
design and (b) the discrete-time multi-state (DTMS) design. Dose 2 is the true
MTD in this trial, and the average toxicity score for the three doses are (0.13, 0.25,
0.53) with decreasing toxicity hazard. The accrual rate r follows an exponential
distribution with mean 1. In figure 4.1(a)(a), each cohort of 3 patients are fully
observed. Dose-escalation decisions are based on the patient’s maximum toxicity
level within 6 weeks. The trial lasts for about 62 weeks. In figure 4.1(b)(b), the
patient’s weekly toxicity level is recorded for dose-escalation decisions. Accrual
is not suspended between cohorts. The trial lasts for about 33 weeks. Escalation
to dose 2 occurred at cohort 3 for the fully-evaluated design, and at cohort 4 for
the DTMS design. Both designs have 2 cohorts of patients on dose 3. The fully-
evaluated design has 1 more cohort of patients on the true MTD. Both designs
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successfully declare dose 2 as the MTD.
4.5.3 Simulation results
Accrual rate R∼ exp(1)
The simulations in this section are based on accrual following an exponential
distribution with mean accrual rate of 1 patient per week. To investigate the
performance of the DTMS design, we use the fully-evaluated design as a compar-
ison and keep all other design parameters the same. Figures 4.3 to 4.6 illustrate
the operating characteristics with ξ = 0.2 and ξ = 0.7. Each figure represents
the simulation results from one of the four toxicity hazard shapes (i.e., constant,
decreasing, increasing or scalloping). Each figure comprises two subfigures: (a)
the left figure shows the results from scenario group 1, for which the ATSd1 is
fixed at 0.13, the ATSd3 is fixed at 0.53 and the ATSd2 is between 0.13 to 0.53;
and (b) the results from scenario group 2, for which the ATSd1 is fixed at 0.05,
the ATSd2 is fixed at 0.13 and the ATSd3 is between 0.13 to 0.53. The joint bars
are the respective results from the fully-evaluated design and the DTMS design.
Under scenarios (a) and (b), the top panel illustrates the average proportion of
patients assigned to each dose. The bottom panel illustrates the MTD selection
percentage for each dose. The unshaded space in the top panel represents the
average proportion of patients not assigned to any dose (out of 30) due to early
stopping. The unshaded space of the bottom panel marks the percentage of trials
in which no dose is declared as the MTD due to early stopping.
For (a) scenario group 1, an ideal design should yield a higher proportion of
patients and selection percentage on dose 2 for the scenarios to the left of the
ATS∗, and a lower proportion of patients and selection percentage on dose 2 and
dose 3 to the right of the ATS∗. For (b) scenario group 2, an ideal design should
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(a) A simulated trial based on the fully-evaluated design
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(b) A simulated trial based on the DTMS design
Time from FPFV (weeks)
Pa
tie
nt
 ID
0 3 6 9 12 15 18 21 24 27 30 33
0
3
6
9
12
15
18
21
24
27
30
D11 1 1 1 1 1
D12 2 2 2 2 5
D13 3 4 4 3 3
D11 1 1 1 1 1
D11 1 1 1 1 1
D11 1 1 1 1 1
D11 1 1 1 1 1
D11 1 1 1 1 1
D11 1 1 1 1 1
D21 1 1 1 1 1
D21 1 1 1 1 1
D21 1 1 1 1 1
D32 2 2 2 1 1
D31 1 1 1 2 2
D31 5 5 5 5 5
D33 1 1 1 1 1
D35 5 5 5 5 5
D31 1 1 1 1 1
D21 1 1 1 1 1
D21 1 1 1 1 1
D21 3 3 4 3 3
D21 1 1 1 1 1
D21 1 1 1 1 1
D21 1 1 1 1 1
D21 1 1 1 1 1
D21 3 3 2 2 2
D21 3 3 3 3 2
D21 1 1 1 2 1
D21 1 1 1 5 5
D21 1 1 1 1 2
True MTD is  D2       Estimated MTD is  D2
Dose−1
Dose−2
Dose−3
Cohort Entry
Figure 4.2: Sample trial conduct based on the alternative designs. The x-axis
indicates the trial time from the first patient’s first visit (FPFV). The y-axis indi-
cates the patient IDs. For each patient, the number at the end of week 6 indicates
the maximum observed toxicity level.
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yield a higher proportion of patients and selection percentage on dose 3 for the
scenarios to the left of the ATS∗, and a lower proportion of patients and selection
percentage on dose 3 to the right of the ATS∗.
The average trial duration based on the fully-evaluated design is approxi-
mately 62 weeks. The average trial duration based on the DTMS design is ap-
proximately 35 weeks. Overall, both the fully-evaluated design and the DTMS
design perform reasonably. All the hazard scenarios yield the same trend in
the operating characteristics: More patients are assigned to the lower doses and
the MTD selection percentage gradually accumulates toward the lower doses as
the higher doses become more toxic. Within scenario group 1, compared to the
fully-evaluated design, the DTMS design assigns a slightly greater proportion of
patients to the higher dose(s), perhaps because it uses incomplete patient toxicity
information at the dose-assessment points. The two alternative designs yield al-
most the same MTD selection percentage. Within scenario group 2, compared to
the fully-evaluated design, the DTMS design assigns a slightly greater proportion
of patients to dose 3 as the ATSd3 increases, and yields a slightly higher MTD
selection percentage on dose 3.
Based on the above observations, for trials with lower accrual and relatively
longer assessment windows, the DTMS design significantly decreases trial dura-
tion and assigns a slightly greater proportion of patients to the higher doses. For
scenarios in which the medium or lower doses are the true MTD (e.g., scenario
group 1), the two alternative designs yield similar MTD selection percentage. For
scenarios in which the higher doses are the true MTD (e.g., scenario group 2),
the DTMS design yields a slightly higher MTD selection percentage.
Figure 4.7 plots the distribution of the posterior mean ATS at the end of
1000 trials for scenario group 1, with the ATSd1 = 0.13, ATSd2 = 0.21 and
ATSd3 = 0.53. Figure 4.8 plots the distribution of the posterior mean ATS at
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the end of 1000 trials for scenario group 2, with the ATSd1 = 0.05, ATSd2 = 0.13
and ATSd3 = 0.21. Both designs yield the most accurate mean estimation of the
ATS on dose 2. The mean ATS for dose 1 is under estimated and the mean ATS
for dose 3 is over-estimated as a result of the isotonic regression on the posterior
ATS.
Accrual rate R∼ Exp(0.5)
The simulations in this section are based on accrual following an exponential dis-
tribution with mean accrual rate of 0.5 patient per week. All other simulation
parameters are unchanged. Figures 4.9 to 4.12 illustrate the operating charac-
teristics of the trial designs, with each figure representing the simulation results
from one of the four toxicity hazard shapes. The average trial duration based on
the fully-evaluated design is approximately 70 weeks. The average trial duration
based on the DTMS design is approximately 63 weeks.
As patient accrual becomes slower, the DTMS design outperforms the fully-
evaluated design in scenario group 1 by assigning slightly more patients to dose
1 and achieving a higher MTD selection percentage on dose 1 as dose 2 becomes
more toxic. The two alternative designs yield very similar operating character-
istics under scenario group 2. Figure 4.13 plots the distribution of the posterior
mean ATS at the end of 1000 trials for scenario group 1 with the ATSd1 = 0.13,
ATSd2 = 0.21, and ATSd3 = 0.53. Figure 4.14 plots the distribution of the
posterior mean ATS at the end of 1000 trials for scenario group 2 with the
ATSd1 = 0.05, ATSd2 = 0.13, and ATSd3 = 0.21.
The results show that the DTMS design offers more benefit compared to the
alternative design as patient accrual becomes slower. This is because more toxic-
ity information is able to accumulate before the time of the next dose-assignment
decision.
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4.5 Simulation comparing the proposed design with the alternative
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4.6 Sensitivity test
4.6 Sensitivity test
This section investigates the sensitivity of the DTMS design to data that are
generated from models that are very different from the model described in Section
4.2. In generating these scenarios, we treat the five toxicity severity levels as
independent events and specify the mean time to each of the events. The time-to-
event data are generated from the exponential model with the prespecified mean.
Based on the time-to-event data, if at least one toxicity level occurs within the
current time interval, we take the maximum toxicity level as the observed toxicity
level for the current time interval. Otherwise, the observed toxicity level will stay
unchanged. The mean time to each toxicity level is selected such that the overall
ATSd for each scenario is the value listed in Table 4.4. All other trial conduct
parameters stay the same as described in the previous sections. Table 4.4 lists
the true ATS scenarios in column 1; the MTD is marked with an asterisk (*).
The average number of patients assigned to each dose is listed in column nd. The
operating characteristics show that the DTMS model performs reasonably. For
scenario 1, in which the true MTD is dose 1, dose 2 is selected with a higher
percentage because the true MTD of dose 2 (0.39) is close to the toxicity target
(0.33).
Table 4.4: Operating characteristics of the sensitivity test
True ATSd MTD selection (%) nd
Scenario 1 0.17∗, 0.39, 0.43 47.2∗, 35.2, 9.3 0.40∗, 0.39, 0.22
Scenario 2 0.13, 0.17∗, 0.43 2.3, 72.6∗, 21.5 0.15, 0.47∗, 0.37
Scenario 3 0.13, 0.17, 0.20∗ 1.0, 6.8, 88.6∗ 0.14, 0.20, 0.66∗
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4.7 Discussion
This chapter introduced an adaptive phase I dose-finding design based on a new
discrete-time multi-state model. The new design categorized toxicity into severity
levels and allows each patient’s early toxicity levels to inform dose escalation.
Compared to other conventional designs that require accrual suspension between
cohorts, the new design significantly shortens trial duration.
The toxicity score wk reflects the severity of the toxicity level k relative to
other toxicity levels. The average toxicity score (ATS) combines all toxicity levels
via wk to reflect the overall toxicity. The isotonic regression process guarantees
that the ATS is monotone across doses and allows the ATS to borrow information
across doses.
If investigators are more interested in characterizing the maximum observed
toxicity level up to the current time interval, we can model the transition of the
maximum observed toxicity level up to the current time interval by assuming that
p(j, k, k
′) = 0 for k > k′. The transition probability matrices are therefore upper
triangle matrices with reduced dimensions.
The DTMS model is ideal for phase I cancer trials that require longer treat-
ment cycles or close monitoring of the toxicity each patient experiences. Com-
puter simulations should be used to direct the accrual rate in order to achieve
desirable operating characteristics. A possible expansion of this design would
be to allow for a temporary suspension of accrual when predictive probabilities
show prohibitively high risks of toxicity for the expected doses of future patients
(Bekele et al. 2008).
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5Summary
This dissertation explored phase I oncology trials from three perspectives: In
Chapter 2 we investigated the current alternative Bayesian dose-assignment rules
based on two probability models. In Chapter 3 we described a phase I dose-
finding design based on a time-to-DLT model with flexible dose-assessment points.
In Chapter 4 we proposed an adaptive phase I dose-finding design based on a
discrete-time multi-state model that incorporates the toxicity level and allows
patients’ partial toxicity information to inform decisions about dose-escalation.
Chapter 2 provided a review and comparison of the four Bayesian decision
rules that summarize the posterior distribution of toxicity in different ways such
that the selected dose’s probability of toxicity is close enough to the target (0.33)
with appropriate overdose control criteria. A modified “3+3” design was also
introduced for comparison as it remains widely used in phase I dose-finding tri-
als. Of the four Bayesian decision rules, ODC selects the next dose based on the
current dose’s posterior distribution of toxicity. The other three rules (CRMr,
MaxTI and Loss) select the next doses based on all doses’ posterior distribution
of toxicity. Unlike CRMr, for which decisions are based on the point estimation
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of the posterior probability of toxicity, the other three Bayesian rules incorporate
uncertainty in summarizing the posterior probability of toxicity. In the simulation
study, we performed intra-rule and inter-rule comparisons for the Bayesian deci-
sion rules based on the beta/binomial model and the logistic regression model,
and compared the results with those from the modified “3+3” algorithm. The
modified “3+3” algorithm is conservative, targeting the toxicity rate between 0.16
and 0.33; therefore, it usually underestimates the MTD. The simulation results
showed that there is no single rule that outperforms the other rules under all the
scenarios. Instead, the four Bayesian decision rules perform similarly in regard to
their operating characteristics, with some rules slightly outperforming the others
under certain scenarios, which we outlined in Chapter 2.
The dose-finding design based on the time-to-DLT model, introduced in Chap-
ter 3, associates time with toxicity information in estimating the probability of
DLT at the end of cycle 1. Dose-escalation decisions are made whenever a cycle-1
DLT occurs, or two months after the previous dose-assessment point. The simu-
lation study showed that the estimation of the end-of-cycle-1 DLT rate is highly
affected by the shape of the toxicity hazard and the follow-up time for the design
based on the time-to-DLT model. For trials in which more late-onset toxicities
are expected, a longer follow-up time (up to 3 cycles) yields a more conservative
MTD selection. These late-onset toxicities are ignored by the design based on
a logistic regression model that uses patients’ binary toxicity information up to
cycle 1, which yields more aggressive MTD selection.
The dose-finding design based on the discrete-time multi-state (DTMS) model,
introduced in Chapter 4, categorizes toxicity into severity levels and considers
the transitions between multiple toxicity severity levels. The model allows pa-
tients’ early toxicity states to inform dose escalation. Thus there is no need to
suspend the enrollment of the next patient or small cohort of patients into the
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trial before the previous patient or cohort has been completely followed. Dose-
escalation decisions are based on the average toxicity score, which combines all
toxicity levels via the toxicity score wk that reflects the severity of the toxicity
level k relative to other toxicity levels. Compared to the fully-evaluated design
that models the maximum observed toxicity level within the patients’ entire as-
sessment window, the DTMS design significantly shortens trial duration. As a
trade-off, the DTMS design assigns a slightly greater proportion of patients to the
higher dose(s), perhaps because it uses incomplete patient toxicity information
at the dose-assessment points. The DTMS design offers more benefit compared
to the alternative design as patient accrual becomes slower because more toxicity
information is able to accumulate before the time of the next dose-assignment
decision.
A model-based phase I dose-finding design includes two frameworks: a statis-
tical model and a dose-escalation rule. The statistical model uses the available
toxicity information to provide the current estimation of the probability of tox-
icity. The dose-escalation rule makes decisions based on the distribution of the
toxicity. This dissertation explored phase I dose-finding designs in cancer trials
from these two frameworks and proposed new designs that target the problems
existing with the traditional designs. Different combinations of the alternative
decision rules and the statistical models may be explored to identify the best
operating characteristics for a specific trial.
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